

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K	A2	(11) International Publication Number: WO 97/33551 (43) International Publication Date: 18 September 1997 (18.09.97)
(21) International Application Number: PCT/US97/04191 (22) International Filing Date: 14 March 1997 (14.03.97) (30) Priority Data: 60/013,438 15 March 1996 (15.03.96) US (71) Applicant: MILLENNIUM PHARMACEUTICALS [US/US]; 640 Memorial Drive, Cambridge, MA 02110 (US). (72) Inventor: SHYJAN, Andrew, W.; 25 Baker Road, Nahant, MA 01908 (US). (74) Agents: FASSE, J., Peter et al.; Fish and Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF NEOPLASTIC CELL GROWTH AND PROLIFERATION (57) Abstract The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that are differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, PREVENTION,
AND TREATMENT OF NEOPLASTIC CELL GROWTH AND PROLIFERATION

1. Background of the Invention

5 The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation, i.e., tumors and cancers (e.g., colon cancer) in mammals, for example, humans. Specifically, genes which are differentially
10 expressed in tumor cells relative to normal cells are identified. Among these are certain novel genes.

 Malignant tumors, i.e., cancers, are the second leading cause of death in the United States, after heart disease (Boring, et al., CA Cancer J. Clin., 43:7, 1993),
15 and develop in one in three Americans. One of every four Americans dies of cancer. Cancer is characterized primarily by an increase in the number of abnormal, or neoplastic, cells derived from a normal tissue which proliferate to form a tumor mass, the invasion of
20 adjacent tissues by these neoplastic tumor cells, and the generation of malignant cells which spread via the blood or lymphatic system to regional lymph nodes and to distant sites. The latter progression to malignancy is referred to as metastasis.

25 Cancer can result from a breakdown in the communication between neoplastic cells and their environment, including their normal neighboring cells. Signals, both growth-stimulatory and growth-inhibitory, are routinely exchanged between cells within a tissue.
30 Normally, cells do not divide in the absence of stimulatory signals, and, likewise, will cease dividing in the presence of inhibitory signals. In a cancerous, or neoplastic, state, a cell acquires the ability to "override" these signals and to proliferate under
35 conditions in which normal cells would not grow.

- 2 -

Tumor cells must acquire a number of distinct aberrant traits to proliferate. Reflecting this requirement is the fact that the genomes of certain well-studied tumors carry several different independently altered genes, including activated oncogenes and inactivated tumor suppressor genes. Each of these genetic changes appears to be responsible for imparting some of the traits that, in aggregate, represent the full neoplastic phenotype (Land et al., Science, 222:771, 1983; Ruley, Nature, 304:602, 1983; Hunter, Cell, 64:249, 1991).

Differential expression of the following suppressor genes has been demonstrated in human cancers: a retinoblastoma gene, RB; the Wilms' tumor gene, WT1 (11p); a gene deleted in colon carcinoma, DCC (18q); the neurofibromatosis type 1 gene, NF1 (17q); and a gene involved in familial adenomatous polyposis coli, APC (5q) (Vogelstein, B. and Kinzler, K.W., Trends Genet., 9:138-141, 1993).

2. Summary of the Invention

The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers, e.g., colon or lung cancer, in mammals, e.g., humans. The invention is based on the discovery of genes that are differentially expressed in tumor cells relative to normal cells of the same tissue. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers (e.g., colon cancer). The genes also can be used in gene therapy, protein synthesis, and to develop antisense nucleic acids.

In general, the invention features an isolated nucleic acid including the nucleotide sequence of any one

- 3 -

of SEQ ID NOS: 2, 4, and 6, or an isolated nucleic acid that hybridizes under stringent hybridization conditions to one of these nucleic acids or their complements. The invention also features a genetically engineered host
5 cell containing one of these nucleotide sequences, and an expression vector containing one of these nucleotide sequences operably linked to a nucleotide sequence regulatory element that controls expression of the nucleotide sequence in a host cell.

10 The invention further features a substantially pure gene product encoded by one of these nucleic acids, e.g., having the amino acid sequence of SEQ ID NO:7. The invention also features an antibody that immunospecifically binds to this gene product.

15 In another embodiment, the invention features a method of diagnosing a tumor in a mammal by obtaining a test sample of tissue cells, e.g., colon cells, from the mammal; obtaining a control sample of known normal cells from the same type of tissue; and detecting in both the
20 test sample and the control sample the level of expression of gene 097, wherein a level of expression higher in the test sample than in the control sample indicates a tumor in the test sample.

The method of diagnosing a tumor can also be
25 carried out using any one or more of genes 030, 036, or 056 wherein a level of expression lower in the test sample than in the control sample indicates a tumor in the test sample.

The invention further features a method of
30 treating a tumor, e.g., a colon tumor, in a patient, e.g., a mammal such as a human, by administering to the mammal a compound in an amount effective to decrease the level of expression or activity of the gene transcript or gene product of gene 097, to a level effective to treat
35 the tumor.

- 4 -

In this method, the compound can be an antisense or ribozyme molecule that blocks translation of the gene transcript, or a nucleic acid complementary to the 5' region of gene 097, and blocks formation of a gene transcript via triple helix formation. The compound also
5 can be an antibody that neutralizes the activity of the gene product.

In another method of treating a tumor in a mammal, a compound is administered in an amount effective to
10 increase the level of expression or activity of the gene transcript or gene product of any one or more of genes 030, 036 and 056, to a level effective to treat the tumor, e.g., colon tumor. In this method, the compound can be a nucleic acid whose administration results in an
15 increase in the level of expression of any one of genes 030, 036 and 056, thereby ameliorating symptoms of the tumor.

In another aspect, the invention features a method for inhibiting tumors in a mammal by administering to the
20 mammal a normal allele of one or more of genes 030, 036 and 056, so that a gene product is expressed, thereby inhibiting tumors. The invention also covers a method for treating tumors in a mammal by administering to the mammal an effective amount of a gene product of any one
25 or more of genes 030, 036 and 056.

The invention also features a method of monitoring the efficacy of a compound in clinical trials for inhibition of tumors, e.g., colon tumors, in a patient by obtaining a first sample of tumor tissue cells from the
30 patient; administering the compound to the patient; after a time sufficient for the compound to inhibit the tumor, obtaining a second sample of tumor tissue cells from the patient; and detecting in the first and second samples the level of expression of gene 097, wherein a level of
35 expression lower in the second sample than in the first

- 5 -

sample indicates that the compound is effective to inhibit a tumor in the patient.

This method can also be carried out using any one or more of genes 030, 036, 056, and 036, wherein a level
5 of expression higher in the second sample than in the first sample indicates that the compound is effective to inhibit a tumor in the patient.

A "tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether
10 malignant or benign, and all pre-cancerous and cancerous cells and tissues.

A "differentially expressed" gene transcript, as used herein, refers to a gene transcript that is found in different numbers of copies, or in activated versus
15 inactivated states, in different cell or tissue types of an organism having a tumor or cancer, e.g., colon cancer, compared to the numbers of copies or state of the gene transcript found in the cells of the same tissue in a healthy organism, or in the cells of the same tissue in
20 the same organism. Multiple copies of gene transcripts may be found in an organism having the tumor or cancer, while only one, or significantly fewer copies, of the same gene transcript are found in a healthy organism or healthy cells of the same tissue in the same organism, or
25 vice-versa.

As used herein, a "differentially expressed gene" refers to (a) a gene containing: at least one of the DNA sequences disclosed herein (as shown in the Figures); (b) any DNA sequence that encodes the amino acid sequences
30 encoded by the DNA sequences disclosed in the Figures; or (c) any DNA sequence that hybridizes to the complement of the sequences disclosed in the Figures under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM
35 EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C

- 6 -

(Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3); or under moderately stringent conditions, i.e., washing in 0.2 x SSC/0.1% SDS at 42°C (Ausubel et al., 1989, supra), yet which still encodes a gene product functionally equivalent to a gene product encoded by a gene of (a) above.

The initial cDNA sequences discovered by the paradigms described below are used to obtain additional cDNA sequences of various lengths up to the full-length cDNA sequences corresponding to individual genes. The individual genes are referred to by a three digit number, e.g., 030, based on the number of the first DNA sequence found that corresponds to that particular gene. In some instances, the paradigm generated two or more DNA sequences that correspond to overlapping or completely unique portions of the full-length cDNA of a gene. In those instances, the gene is referred to by the number of the first DNA sequence found to correspond to that gene.

A "differentially expressed gene," can be a target, fingerprint, or pathway gene. For example, a "fingerprint gene," as used herein, refers to a differentially expressed gene whose expression pattern can be used as a prognostic or diagnostic marker for the evaluation of tumors and cancers, or which can be used to identify compounds useful for the treatment of tumors and cancers, e.g., colon or lung cancer. For example, the effect of a compound on the fingerprint gene expression pattern normally displayed in connection with tumors and cancers can be used to evaluate the efficacy of the compound as a tumor and cancer treatment, or can be used to monitor patients undergoing clinical evaluation for the treatment of tumors and cancer.

- 7 -

A "fingerprint pattern," as used herein, refers to a pattern generated when the expression pattern of a series (which can range from two up to all the fingerprint genes that exist for a given state) of fingerprint genes is determined. A fingerprint pattern can be used in the same diagnostic, prognostic, and compound identification methods as the expression of a single fingerprint gene.

A "target gene," as used herein, refers to a differentially expressed gene in which modulation of the level of gene expression or of gene product activity prevents and/or ameliorates tumor and cancer, e.g., colon cancer, symptoms. Thus, compounds that modulate the expression of a target gene or the activity of a target gene product can be used in the treatment or prevention of tumors and cancers.

"Pathway genes," as used herein, are genes that encode proteins or polypeptides that interact with other gene products involved in tumors and cancers. Pathway genes can also exhibit target gene and/or fingerprint gene characteristics.

By "substantially identical" is meant a polypeptide or nucleic acid having a sequence that has at least 85%, preferably 90%, and more preferably 95%, 98%, 99% or more identity to the sequence of a reference nucleic acid sequence, e.g., the nucleic acid sequence of SEQ ID NO:6.

The nucleic acid molecules of the invention can be inserted into transcription and/or translation vectors, as described below, which will facilitate expression of the insert. The nucleic acid molecules and the polypeptides they encode can be used directly as diagnostic or therapeutic agents, or (in the case of a polypeptide) can be used to generate antibodies that, in turn, are therapeutically useful. Accordingly,

- 8 -

expression vectors containing the nucleic acid molecules of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic
5 fragment thereof, are among the preferred embodiments.

As used herein, the term "transfected cell" means any cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid encoding a polypeptide of the invention.

10 By "isolated nucleic acid molecule" is meant a nucleic acid molecule that is separated from the 5' and 3' coding sequences with which it is immediately contiguous in the naturally occurring genome of an organism. Thus, the term "isolated nucleic acid
15 molecule" includes nucleic acid molecule which are not naturally occurring, e.g., nucleic acid molecules created by recombinant DNA techniques.

The term "nucleic acid molecule" encompasses both RNA and DNA, including cDNA, genomic DNA, and synthetic
20 (e.g., chemically synthesized) DNA. Where single-stranded, the nucleic acid may be a sense strand or an antisense strand.

The polypeptides of the invention can also be chemically synthesized, or they can be purified from
25 tissues in which they are naturally expressed, according to standard biochemical methods of purification.

Also included in the invention are "functional polypeptides," which possess one or more of the biological functions or activities of a protein or
30 polypeptide of the invention. These functions or activities include the ability to bind some or all of the proteins which normally bind to gene 036 protein.

The functional polypeptides may contain a primary amino acid sequence that has been modified from those
35 disclosed herein. Preferably these modifications consist

- 9 -

of conservative amino acid substitutions, as described herein.

The terms "protein" and "polypeptide" are used herein to describe any chain of amino acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation). Thus, the term "polypeptide" includes full-length, naturally occurring proteins as well as recombinantly or synthetically produced polypeptides that correspond to a full-length naturally occurring protein or to particular domains or portions of a naturally occurring protein. The term also encompasses mature proteins which have an added amino-terminal methionine to facilitate expression in prokaryotic cells).

The term "purified" as used herein refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

Polypeptides or other compounds of interest are said to be "substantially pure" when they are within preparations that are at least 60% by weight (dry weight) the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. Purity can be measured by any appropriate standard method, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

A polypeptide or nucleic acid molecule is "substantially identical" to a reference polypeptide or nucleic acid molecule if it has a sequence that is at least 85%, preferably at least 90%, and more preferably at least 95%, 98%, or 99% identical to the sequence of the reference polypeptide or nucleic acid molecule.

- 10 -

Where a particular polypeptide is said to have a specific percent identity to a reference polypeptide of a defined length, the percent identity is relative to the reference peptide. Thus, a peptide that is 50% identical
5 to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It might also be a 100 amino acid long polypeptide which is 50% identical to the reference
10 polypeptide over its entire length. Of course, many other polypeptides will meet the same criteria.

In the case of polypeptide sequences which are less than 100% identical to a reference sequence, the non-identical positions are preferably, but not
15 necessarily, conservative substitutions for the reference sequence. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and
20 threonine; lysine and arginine; and phenylalanine and tyrosine.

For polypeptides, the length of the reference polypeptide sequence will generally be at least 16 amino acids, preferably at least 20 amino acids, more
25 preferably at least 25 amino acids, and most preferably 35 amino acids, 50 amino acids, or 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at
30 least 75 nucleotides, and most preferably 100 nucleotides or 300 nucleotides.

Sequence identity can be measured using sequence analysis software (for example, the Sequence Analysis Software Package of the Genetics Computer Group, .
35 University of Wisconsin Biotechnology Center, 1710

- 11 -

University Avenue, Madison, WI 53705), with the default parameters as specified therein.

The nucleic acid molecules of the invention can be inserted into a vector, as described below, which will facilitate expression of the insert. The nucleic acid molecules and the polypeptides they encode can be used directly as diagnostic or therapeutic agents, or can be used (directly in the case of the polypeptide or indirectly in the case of a nucleic acid molecule) to generate antibodies that, in turn, are clinically useful as a therapeutic or diagnostic agent. Accordingly, vectors containing the nucleic acid of the invention, cells transfected with these vectors, the polypeptides expressed, and antibodies generated, against either the entire polypeptide or an antigenic fragment thereof, are among the preferred embodiments.

As used herein, the term "transformed cell" means a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule encoding a polypeptide of the invention.

The invention also features antibodies, e.g., monoclonal, polyclonal, and engineered antibodies, which specifically bind proteins and polypeptides of the invention, e.g., gene 036 protein. By "specifically binds" is meant an antibody that recognizes and binds to a particular antigen, e.g., a gene 036 polypeptide of the invention, but which does not substantially recognize or bind to other molecules in a sample, e.g., a biological sample.

The invention also features antagonists and agonists of gene 036 protein that can inhibit or enhance one or more of the functions or activities of gene 036 protein or other proteins of the invention, respectively. Suitable antagonists can include small molecules (i.e.,

- 12 -

molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500), antibodies that bind and "neutralize" gene 036 protein (as described below), polypeptides which
5 compete with a native form of gene 036 protein for binding to a protein which naturally interacts with gene 036 protein, and nucleic acid molecules that interfere with transcription of a gene of the invention (for example, antisense nucleic acid molecules and ribozymes).
10 Useful agonists also include small and large molecules, and antibodies other than "neutralizing" antibodies.

The invention also features molecules which can increase or decrease the expression of a gene of the invention (e.g., by influencing transcription or
15 translation). Small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500), and nucleic acid molecules that can be used to inhibit the expression of a gene of the invention for example,
20 antisense and ribozyme molecules) or to enhance their expression (for example, expression constructs that place nucleic acid sequences encoding proteins of the invention, e.g., gene 036 protein under the control of a strong promoter system), and transgenic animals that
25 express a gene 036 transgene.

The invention also includes nucleic acid molecules, preferably DNA, that hybridize to the DNA sequences (a) through (c), above, of a differentially expressed gene. Hybridization conditions can be highly
30 stringent or moderately stringent, as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("oligos"), highly stringent conditions are defined as washing in 6 x SSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-
35 base oligos), 55°C (for 20-base oligos), and 60°C (for

- 13 -

23-base oligos). These nucleic acid molecules can act as target gene antisense molecules, useful in target gene regulation, or as antisense primers in amplification reactions of target, fingerprint, and/or pathway gene
5 nucleic acid sequences. Further, such sequences can be used as part of ribozyme and/or triple helix sequences, also useful for target gene regulation. Still further, such molecules can be used in diagnostic methods to detect tumors and cancers, e.g., colon cancer, and a
10 patient's predisposition towards tumors or cancers.

The invention also encompasses (a) DNA vectors that contain any of the foregoing coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing coding
15 sequences operatively associated with a regulatory element that directs the expression of the coding sequences; and (c) genetically engineered host cells that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs the
20 expression of the coding sequences in the host cell. As used herein, "regulatory elements" include, but are not limited to, inducible and non-inducible promoters, enhancers, operators, and other elements known to those skilled in the art that drive and regulate expression.
25 The invention includes fragments of any of the DNA sequences disclosed herein.

A "detectable" RNA expression level, as used herein, means a level that is detectable by the standard techniques of differential display, RT (reverse
30 transcriptase)-coupled polymerase chain reaction (PCR), Northern, and/or RNase protection analyses. The degree to which expression differs need only be large enough to be visualized via standard characterization techniques, such as, for example, the differential display technique
35 described below.

- 14 -

Based on the expression patterns in the paradigm results described below (e.g., Table 1), the following genes: 030, 036 (095), and 056, are expressed at a higher level in normal colon tissues than in cancerous
5 colon tissues. Specifically, the data show a correlation between an increase in the expression level of these genes and a decrease in a colon cell's tumor potential. In other words, a reduction of the expression level of these genes in a cell may induce or predispose the cell
10 to become cancerous. Hence, methods that increase the level of expression of these genes may inhibit or slow the progression to tumors and cancers, e.g., colon cancer.

On the other hand, further based on the expression
15 patterns in the paradigm results described below (e.g., Table 1), gene 097 is expressed at a higher level in colon tumor tissues than in normal colon tissues. Specifically, the data show a correlation between an increase in the expression level of these genes and an
20 increase in a colon cell's cancer potential. In other words, a reduction of the expression level of these genes in a cell may induce or predispose that cell to remain normal. Hence, methods that decrease the level of
expression of these genes may inhibit or slow the
25 progression to tumors and cancers, e.g., colon cancer.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and
30 materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are
35 incorporated by reference in their entirety. In case of

- 15 -

conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

5 Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

3. Brief Description of the Drawings

Figs. 1a to 1e are a series of DNA sequence
10 fragments (SEQ ID NOS:1 to 5) from genes detected by the paradigms described herein.

Fig. 2 is the DNA (SEQ ID NO:23) of gene 036 and the amino acid sequence (SEQ ID NO:24) encoded by gene 036.

4. Detailed Description

This invention is based, in part, on systematic search strategies involving a biological specimen
paradigm of tumors and cancers, coupled with sensitive and high-throughput gene expression assays, to identify
20 genes differentially expressed in tumor cells relative to normal cells of the same organ or tissue (either within the same individual, or in different organisms, one with a tumor and other healthy). In contrast to approaches that merely evaluate the expression of a given gene
25 product presumed to play a role in one or another type of cancer, the search strategies and assays used herein permit the identification of all genes, whether known or novel, that are differentially expressed in tumor cells relative to normal cells. Further, the method is
30 independent of gene copy number, and thus allows detection of even low copy number genes that are differentially expressed.

- 16 -

This comprehensive approach and evaluation permits the discovery of novel genes and gene products, as well as the identification of an array of genes and gene products (whether novel or known) involved in novel pathways that play a major role in tumor pathology. Thus, the present invention allows the identification and characterization of targets useful for prognosis, diagnosis, monitoring, rational drug design, and/or other therapeutic intervention of tumors and cancers.

The Examples below demonstrate the successful use of search strategies of the invention to identify genes that are differentially expressed in colon tumor cells relative to normal colon cells. These genes, referred to herein by different numbers, include novel and known genes which are expressed at a many-fold higher or lower level in tumor cells relative to their expression in normal cells of same tissue.

4.1. Identification of Differentially Expressed Genes

There exist a number of levels or stages at which the differential expression of differentially expressed genes can be exhibited. For example, differential expression can occur in tumor cells versus normal cells, or in tumor cells in different stages of progression. For example, genes can be identified that are differentially expressed in pre-neoplastic versus neoplastic cells. Such genes can, for example, promote unhindered cell proliferation or tumor cell invasion of adjacent tissue, both of which are viewed as hallmarks of the neoplastic state. Further, differential expression can occur among cells within any one of different states, e.g., pre-neoplastic, neoplastic, and metastatic, and can indicate, for example, a difference in severity or aggressiveness of one cell relative to that of another cell within the same state.

- 17 -

4.1.1. Paradigms for the Identification of Differentially Expressed Genes

Different paradigms can be used to identify particular genes. One such paradigm, referred to herein as the "specimen paradigm," uses surgical and biopsy samples. For example, such samples can represent normal colon tissue or primary, secondary, or metastasized colon tumor tissue obtained from patients having undergone surgical treatment for colon cancer.

10 Surgical samples can be procured under standard conditions involving freezing and storing in liquid nitrogen (see, for example, Karmali et al., Br. J. Cancer, 48:689-696, 1983). RNA from sample cells is isolated by, for example, differential centrifugation of
15 homogenized tissue, and analyzed for differential expression relative to other specimen cells, preferably cells obtained from the same patient.

In another paradigm, referred to herein as the "in vitro" paradigm, cell lines, rather than tissue samples,
20 can be used to identify genes that are differentially expressed in tumors and cancers (e.g., lung or colon cancer). Differentially expressed genes are detected, by comparing the pattern of gene expression between experimental and control conditions. In such a paradigm,
25 genetically matched colon tumor and normal colon cell lines, e.g., variants of the same cell line, are used, one of which exhibits a tumorous phenotype, while the other exhibits a normal colon cell phenotype.

In accordance with this aspect of the invention,
30 the sample cells are harvested, and RNA is isolated and analyzed for differentially expressed genes, as described in detail in Section 4.1.2. Examples of cell lines that can be used in the in vitro paradigm include but are not limited to variants of human colon cell lines, such as,
35 for example Caco-2 (ATCC HTB-37), a human colon adenocarcinoma cell line, and HT-29 (ATCC HTB-38), a

- 18 -

moderately well-differentiated grade II human colon adenocarcinoma cell line.

In a third paradigm, referred to herein as the in vivo paradigm, animal models of tumors and cancers (e.g., colon cancer) can be used to discover differentially expressed gene sequences. The in vivo nature of such models can prove to be especially predictive of the analogous responses in patients. A variety of tumor and cancer animal models can be used in the in vivo paradigms. For example, animal models of colon cancer can be generated by passaging tumor cells in animals, e.g., mice, leading to the appearance of tumors within these animals. See, e.g., the description of an orthotopic transplant model of human colon cancer in nude mice in Wang et al., Cancer Research, 54:4726-4728 (1994) and Togo et al., Cancer Research, 55:681-684 (1995). This mouse model is based on the so-called "METAMOUSE"™ sold by AntiCancer, Inc. (San Diego, CA).

Additional animal models, some of which may exhibit differing tumor and cancer characteristics, can be generated from the original animal models described above. For example, the tumors that arise in the original animals can be removed and grown in vitro. Cells from these in vitro cultures can then be passaged in animals, and tumors resulting from this passage can be isolated. RNA from pre-passage cells, and cells isolated after one or more rounds of passage can be isolated and analyzed for differential expression. Such passaging techniques can use any known tumor or cancer cell lines. Additionally, animal models for tumors and cancers that can be used in the in vivo paradigm include any of the animal models described in Section 4.7.1.

Compounds known to have an ameliorative effect on tumor and cancer (e.g., colon cancer) symptoms, e.g., alkylating agents such as semustine (N-(2-chloroethyl)-

- 19 -

N'-4-methylcyclohexyl)-N-nitrosourea) and lomustine (N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea (CCNU)), also can be used in the paradigms to detect differentially expressed genes. For example, tumor cells that are
5 cultured can be exposed to one of these compounds and analyzed for differential gene expression with respect to untreated tumor cells, according to the methods described below in Section 4.1.2. In principle, however, according to the paradigm, any cell type involved in a tumor or
10 cancer can be treated by these compounds at any stage of the tumor process.

Cells involved in tumors and cancers can also be compared to unrelated cells, e.g., fibroblasts, that have been treated with the compound, such that any generic
15 effects on gene expression that might not be related to the disease or its treatment can be identified. Such generic effects might be manifest, for example, by changes in gene expression that are common to the test cells and the unrelated cells upon treatment with the
20 compound.

By these methods, the genes and gene products upon which these compounds act can be identified and used in the assays described below to identify novel therapeutic compounds for inhibition and treatment of tumors and
25 cancers (e.g., colon cancer).

4.1.2. Analysis of Paradigm Material

To identify differentially expressed genes, total RNA is isolated from cells utilized in the paradigms described above. Any RNA isolation technique that does
30 not select against the isolation of mRNA can be utilized for the purification of such RNA samples. See, for example, Ausubel, F.M. et al., eds., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. New York (1987-1993). Additionally, large numbers of tissue
35 samples can be processed using techniques well known to

- 20 -

those of skill in the art, e.g., the single-step RNA isolation process of Chomczynski, U.S. Patent No. 4,843,155 (1989).

Transcripts within the collected RNA samples which
5 represent RNA produced by differentially expressed genes can be identified by using a variety of methods that are well known to those of skill in the art. For example, differential screening (Tedder et al., Proc. Natl. Acad. Sci. USA, 85:208-212, 1988), subtractive hybridization
10 (Hedrick et al., Nature, 308:149-153, 1984; Lee et al., Proc. Natl. Acad. Sci. USA, 88:2825, 1984), and, preferably, differential display (Pardee et al., U.S. Patent No. 5,262,311, 1993), can be utilized to identify nucleic acid sequences derived from genes that are
15 differentially expressed.

Differential screening involves the duplicate screening of a cDNA library in which one copy of the library is screened with a total cell cDNA probe corresponding to the mRNA population of one cell type,
20 while a duplicate copy of the cDNA library is screened with a total cDNA probe corresponding to the mRNA population of a second cell type. For example, one cDNA probe corresponds to a total cell cDNA probe of a cell type or tissue derived from a control (healthy) subject,
25 while the second cDNA probe corresponds to a total cell cDNA probe of the same cell type derived from an experimental subject, e.g., with a tumor or cancer (e.g., colon cancer), or from tumorous cells or tissue in the same subject. Those clones that hybridize to one probe
30 but not to the other potentially represent clones derived from genes differentially expressed in the cell type of interest in control versus experimental subjects.

Subtractive hybridization techniques generally involve the isolation of mRNA taken from two different
35 sources, e.g., control and experimental tissue, the

- 21 -

hybridization of the mRNA or single-stranded cDNA reverse-transcribed from the isolated mRNA, and the removal of all hybridized, and therefore double-stranded, sequences. The remaining non-hybridized, single-stranded cDNAs, potentially represent clones derived from genes that are differentially expressed in the two mRNA sources. Such single-stranded cDNAs are then used as the starting material for the construction of a library comprising clones derived from differentially expressed genes.

The differential display technique is a procedure using the well-known polymerase chain reaction (PCR) described in Mullis, U.S. Patent No. 4,683,202 (1987), which enables the identification of sequences derived from differentially expressed genes. First, isolated RNA is reverse-transcribed into single-stranded cDNA by standard techniques. Primers for the reverse transcriptase reaction can include, but are not limited to, oligo dT-containing primers, preferably of the 3' primer type of oligonucleotides described below.

Next, this technique uses pairs of PCR primers, as described below, which allow for the amplification of clones representing a random subset of the RNA transcripts present within any given cell. Each of the mRNA transcripts present in a cell can be amplified by using different pairs of primers. Among such amplified transcripts can be identified those which have been produced from differentially expressed genes.

The 3' oligonucleotide primer of the primer pairs can contain an oligo dT stretch of 10-13, preferably 11, dT nucleotides at its 5' end, which hybridizes to the poly(A) tail of mRNA or to the complement of a cDNA reverse transcribed from an mRNA poly(A) tail. Second, the 3' primer can contain one or more, preferably two, additional nucleotides at its 3' end to increase its

- 22 -

specificity. Because, statistically, only a subset of the mRNA-derived sequences in the sample will hybridize to such primers, the additional nucleotides allow the primers to amplify only a subset of the mRNA-derived
5 sequences present in the sample of interest. This is preferred because it allows more accurate and complete visualization and characterization of each of the bands representing amplified sequences.

The 5' primer can contain a nucleotide sequence
10 expected, statistically, to hybridize to cDNA sequences derived from the tissues of interest. The nucleotide sequence can be an arbitrary one, and the length of the 5' oligonucleotide primer can range from about 9 to about 15 nucleotides, with about 13 nucleotides being
15 preferred. Additionally, arbitrary primer sequences cause the lengths of the amplified partial cDNAs produced to be variable, thus allowing different clones to be separated by standard denaturing sequencing gel electrophoresis.

20 PCR reaction conditions should optimize amplified product yield and specificity and produce amplified products of lengths that can be resolved using standard gel electrophoresis techniques. Such reaction conditions are well known to those of skill in the art, and
25 important reaction parameters include, for example, length and nucleotide sequence of oligonucleotide primers, and annealing and elongation step temperatures and reaction times.

The pattern of clones resulting from the reverse
30 transcription and amplification of the mRNA of two different cell types is displayed via sequencing gel electrophoresis and compared. Differences in the two banding patterns indicate potentially differentially expressed genes.

- 23 -

Once potentially differentially expressed gene sequences have been identified by such bulk techniques, the differential expression should be corroborated. Corroboration can be accomplished, e.g., by such well-known techniques as Northern analysis, quantitative RT-coupled PCR, or RNase protection.

Also, amplified sequences of differentially expressed genes can be used to isolate the full-length clones of the corresponding gene. The full-length coding portion of the gene can be readily isolated by molecular biological techniques well known in the art. For example, the isolated, amplified fragment can be labeled and used to screen a cDNA or genomic library.

PCR technology also can be used to isolate full-length cDNA sequences. As described in this section above, the isolated amplified gene fragments (of about at least 10 nucleotides, preferably longer, of about 15 nucleotides) have their 5' terminal end at some random point within the gene, and have 3' terminal ends at a position corresponding to the 3' end of the transcribed portion of the gene. Once nucleotide sequence information from an amplified fragment is obtained, the remainder of the gene, i.e., the 5' end of the gene, when utilizing differential display, can be obtained using, for example, RT PCR.

In one embodiment of such a procedure for the identification and cloning of full-length gene sequences, RNA is isolated, following standard procedures, from an appropriate tissue or cellular source. A reverse transcription reaction is then performed on the RNA using an oligonucleotide primer complementary to the mRNA that corresponds to the amplified cloned fragment, for the priming of first strand synthesis. Because the primer is anti-parallel to the mRNA, extension will proceed toward the 5' end of the mRNA. The resulting RNA/DNA hybrid is

- 24 -

then "tailed" with guanines using a standard terminal transferase reaction, the hybrid is digested with RNAase H, and second strand synthesis is then primed with a poly-C primer.

5 Using the two primers, the 5' portion of the gene is then amplified using PCR. Sequences obtained are then isolated and recombined with previously isolated sequences to generate a full-length cDNA of the differentially expressed genes of the invention. For a
10 review of suitable cloning strategies and recombinant DNA techniques, see, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, (Cold Springs Harbor Press, N.Y., 1989); and Ausubel et al., Current Protocols in Molecular Biology, (Green Publishing Associates and Wiley
15 Interscience, N.Y., 1989).

4.2. Methods for the Identification of Pathway Genes

Any method suitable for detecting protein-protein interactions can be employed to identify pathway gene products by identifying interactions between gene
20 products and gene products known to be involved in tumors and cancers, e.g., those involved in colon cancer as described herein. Such known gene products can be cellular or extracellular proteins. Those gene products that interact with known gene products represent pathway
25 gene products and the genes which encode them represent pathway genes.

Among the traditional methods that can be employed to identify pathway gene products are cross-linking, co-immunoprecipitation, and co-purification through
30 gradients or chromatographic columns. Once identified, a pathway gene product can be used with standard techniques to identify its corresponding pathway gene. For example, at least a portion of the amino acid sequence of the pathway gene product can be ascertained using techniques

- 25 -

well known to those of skill in the art, such as via the Edman degradation technique (see, e.g., Creighton, Proteins: Structures and Molecular Principles, (W.H. Freeman & Co., N.Y., 1983), pp. 34-49). The amino acid
5 sequence obtained can be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for pathway gene sequences. Screening can be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of
10 oligonucleotide mixtures and the screening are well known (see, e.g., Ausubel, supra, and Innis et al. (eds.), PCR Protocols: A Guide to Methods and Applications, (Academic Press, Inc., New York, 1990)).

Additionally, methods can be employed to
15 simultaneously identify pathway genes that encode a protein interacting with a protein related to a tumor or cancer (e.g., colon cancer). These methods include, for example, probing expression libraries with a labeled protein that is known or suggested to be involved in a
20 tumor or cancer, e.g., a protein encoded by the differentially expressed genes described herein, using this protein in a manner similar to the well known technique of antibody probing of λ gt11 libraries.

One method that detects protein interactions in vivo, the yeast two-hybrid system, is described in detail
25 below for illustration only and not by way of limitation. One version of this system has been described in Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-9582 (1991), and is commercially available from Clontech (Palo Alto, CA).

30 Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins: the first hybrid protein consists of the DNA-binding domain of a transcription factor, e.g., activation protein, fused to a known protein, in this case, a protein known to be
35 involved in a tumor or cancer, and the second hybrid

- 26 -

protein consists of the transcription factor's activation domain fused to an unknown protein that is encoded by a cDNA which has been recombined into this plasmid as part of a cDNA library. The plasmids are transformed into a strain of the yeast *Saccharomyces cerevisiae* that contains a reporter gene, e.g., *lacZ*, whose expression is regulated by the transcription factor's binding site.

Either hybrid protein alone cannot activate transcription of the reporter gene. The DNA binding hybrid protein cannot activate transcription because it does not provide the activation domain function, and the activation domain hybrid protein cannot activate transcription because it lacks the domain required for binding to its target site, i.e., it cannot localize to the transcription activator protein's binding site. Interaction between the DNA binding hybrid protein and the library encoded protein reconstitutes the functional transcription factor and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

The two-hybrid system or similar methods can be used to screen activation domain libraries for proteins that interact with a known "bait" gene product. By way of example, and not by way of limitation, gene products, e.g., of the genes described herein, known to be involved in a particular tumor or cancer, e.g., colon cancer, can be used as the bait gene products. Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of the bait gene product fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene. For example, and not by way of limitation, the bait gene can be cloned into a vector such that it is translationally fused to the DNA encoding

- 27 -

the DNA-binding domain of the GAL4 protein. The colonies are purified and the (library) plasmids responsible for reporter gene expression are isolated. The inserts in the plasmids are sequenced to identify the proteins
5 encoded by the cDNA or genomic DNA.

A cDNA library of a cell or tissue source that expresses proteins predicted to interact with the bait gene product can be made using methods routinely practiced in the art. According to the particular system
10 described herein, the library is generated by inserting the cDNA fragments into a vector such that they are translationally fused to the activation domain of GAL4. This library can be co-transformed along with the bait gene-GAL4 fusion plasmid into a yeast strain which
15 contains a lacZ gene whose expression is controlled by a promoter which contains a GAL4 activation sequence. A cDNA encoded protein, fused to GAL4 activation domain, that interacts with the bait gene product will reconstitute an active GAL4 transcription factor and
20 thereby drive expression of the lacZ gene. Colonies that express lacZ can be detected by their blue color in the presence of X-gal. cDNA containing plasmids from such a blue colony can then be purified and used to produce and isolate the bait gene product interacting protein using
25 techniques routinely practiced in the art.

4.3. Characterization of Differentially Expressed and Pathway Genes

Differentially expressed genes, such as those identified via the methods discussed above in Section
30 4.1, and pathway genes, such as those identified via the methods discussed above in Section 4.2, as well as genes identified by alternative means, can be further characterized by using methods such as those discussed herein. Such genes will be referred to herein as
35 "identified genes."

- 28 -

Any of the differentially expressed genes whose modulation of the gene's expression, or a modulation of the gene product's activity can inhibit tumors and cancers will be designated "target genes," as defined above. Any of the differentially expressed genes or pathway genes whose modulation does not positively affect tumors and cancers, but whose expression pattern contributes to a gene expression "fingerprint" pattern correlative of tumors and cancers will be designated "fingerprint genes." Each of the target genes can also function as a fingerprint gene, as can all or a portion of the pathway genes.

A variety of techniques can be used to further characterize the identified genes. First, the nucleotide sequence of the identified genes, which can be obtained by standard techniques, can be used to further characterize such genes. For example, the sequence of the identified genes can reveal homologies to one or more known sequence motifs which can yield information regarding the biological function of the identified gene product.

Second, the tissue and/or cell type distribution of the mRNA produced by the identified genes can be analyzed using standard techniques, e.g., Northern analyses, RT-coupled PCR, and RNase protection techniques. Such analyses provide information as to whether the identified genes are expressed in tumorous tissues, e.g., in colon cancer. Such analyses can also provide quantitative information regarding steady state mRNA regulation. Additionally, standard in situ hybridization techniques can be used to provide information regarding which cells within a given tissue express the identified gene.

Third, the sequences of the identified genes can be localized onto genetic maps, e.g., mouse (Copeland et

- 29 -

al., Trends in Genetics, 7:113-118, 1991) and human genetic maps (Cohen, et al., Nature, 366:698-701, 1993). Such mapping information can yield information regarding the genes' importance to human disease by, for example, identifying genes that map within genetic regions to which known tumors and cancers map. For example, Vogelstein et al., Science, 244:207-211 (1989), describes allelic deletions in different chromosomes associated with colorectal carcinomas in humans.

Fourth, the biological function of the identified genes can be more directly assessed in relevant in vivo and in vitro systems. In vivo systems can include, but are not limited to, animals that naturally exhibit symptoms of tumors or cancers, or animals engineered to exhibit such symptoms. For example, colon cancer animal models can be generated by injecting animals, such as mice, with colon tumor cells, some of which will give rise to tumors.

The role of identified gene products, e.g., gene products of the genes identified herein, can be determined by transfecting cDNAs encoding these gene products into appropriate cell lines, such as, for example, Caco-2 and HT29, and analyzing the effect on tumor (e.g., colon cancer) characteristics. For example, the role and function of genes important in the progression of human colon cancer are assessed using the cells implanted into nude mice ceca and the number of tumors that develop are determined. Tumor volume and number of metastases are also determined. Tumor growth can also be observed in vitro in soft agar, which typically does not support growth of normal cells. The function of genes isolated using human colorectal tumors and their hepatic metastases are assessed by expressing the gene in the appropriate model, e.g., the METAMOUSE™ model described above.

- 30 -

4.4. Differentially Expressed and Pathway Genes

The differentially expressed and pathway genes of the invention are listed below in Table 1. Nucleotide sequences corresponding to differentially expressed genes
5 are shown in Figs. 1a to 1e and Fig. 2. Specifically, Figs. 1a to 1e depict the nucleotide sequences of the amplified cDNA sequences initially identified via differential display analysis. Fig. 2 depicts a cDNA sequence corresponding to a gene of the invention.

10 Table 1 summarizes information regarding the further characterization of the differentially expressed genes of the invention detected in the specimen paradigm. Table 1 lists SEQ ID NOs, figure numbers, chromosome location (where determined), and references to similar or
15 identical sequences found in nucleic acid databases ("Database Hits"). No references are listed for novel genes, i.e., where no identical gene sequences were found in published databases.

Further in Table 1, in the column headed "Higher
20 Expression In," "N" indicates that gene expression was higher in normal (e.g., non-tumorous) cells, i.e., there was a greater steady state amount of detectable mRNA produced by a given gene in the normal cells than in
tumor cells, while "T" indicates that gene expression was
25 higher in tumor cells, i.e., there was a higher steady state amount of detectable mRNA produced by a given gene in the tumor colon cells than in the normal colon cells. Table 1 also shows the results of RT-PCR. "Nd" indicates
"not done."

30 In the table, numbers in parenthesis in the "RT-PCR" column show the number of positive samples, i.e., samples that confirmed the results of the expression pattern in the differential display specimen paradigm, over the number of total samples (8 or 12)
35 assayed. A "+" indicates a positive result. When

- 31 -

relevant, the number/name of the human chromosome to which the cDNA sequence mapped is given.

The full-length cDNA sequences of the genes listed in Table 1 can be obtained using methods well known to those skilled in the art, including, but not limited to, the use of appropriate probes to detect the genes within an appropriate cDNA or gDNA (genomic DNA) library (see, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, 1989). Another technique for obtaining a full-length cDNA that can be used instead of, or in conjunction with, library screening is the so-called "RACE" technique, which stands for rapid amplification of cDNA ends.

Oligonucleotide probes corresponding to the DNA sequences reported herein can be synthesized, using techniques well known to those of skill in the art, based on the DNA sequences disclosed herein in Figs. 1a to 1e and Fig. 2. The probes can be used to screen cDNA libraries prepared from an appropriate cell or cell line in which the gene is transcribed. For example, PCR primers based on the nucleotide sequences in Figs. 1a to 1e and Fig. 2 can be used to probe human tissue libraries to determine if a given gene is present. Then, labelled probes are used to screen the libraries to obtain the desired gene.

In particular, useful human tissue cDNA libraries are available from, e.g., Clontech (Palo Alto, CA), and include: brain (HL1065a), colon (HL1034a), colon cancer (HL1148a), liver (HL1115a), lung (HL1158a), and kidney (HL1033a) libraries. A human muscle cDNA library is available from Stratagene (La Jolla, CA). These or other human tissue cDNA libraries are screened using probes based on the DNA fragments of Figs. 1a to 1e and 2. Duplicate filters with a total of one million phage from the cDNA library are hybridized in 5 x SSCPE, 5 x

- 32 -

Denhard's solution, and 50% formamide with about 10^6 cpm per ml of radiolabeled DNA probe. The filters are washed to a final stringency of 0.5 x SSCPE and 0.1% SDS at 65°C and exposed to Kodak XPR film at -80°C with an

5 intensifying screen. λ phage hybridizing to the probe on duplicate filters are plaque-purified and their cDNA inserts sequenced using standard techniques.

Another standard technique for obtaining full-length cDNAs from a known DNA sequence is the RACE
10 technique. This technique can be carried out using Clontech's MARATHON™ ready cDNAs (e.g., Human Lung, Cat# 7408-1, Human Brain, Cat#7400-1) and Adaptor primers (AP1 and AP2) (Clontech, Palo Alto, CA). In this method, two
15 nested 30-35mer gene-specific oligos are generated from a known cDNA sequence (with orientation specific for generating either 3 or 5' RACE products), and are used to extend the ends of the known sequence.

RACE was performed for a variety of the cDNA fragments described in Figs. 1a to 1e using MARATHON-
20 ready cDNA as a template, the distal gene-specific primer, the AP1 adaptor primer, ExTaq DNA polymerase (PanVera, Madison WI) and a TaqStart antibody (Clontech, Palo Alto, CA). Reaction conditions were as follows: 94°C for 1 minutes, then 5 cycles of 94°C for 30 seconds,
25 72°C for 4 minutes, then 5 cycles of 94°C for 30 seconds, 70°C for 4 minutes, then 20 cycles of 94°C for 20 seconds, then 68°C for 4 minutes.

1/50th of the initial PCR reaction was used as template with the nested gene-specific primer and the AP2
30 adaptor primer, using the same conditions. All products were analyzed by electrophoresis, and resultant bands were gel-isolated and cloned directly, or the separated PCR products were Southern blotted and hybridized with another gene-specific oligo to determine which products
35 were of interest.

- 33 -

To clone human genomic DNA corresponding to a full-length cDNA, a cDNA fragment can be used to probe human high density PAC filters from Genome Systems, Inc. (St. Louis, MO, Catalog No. FPAC-3386). The probe is
5 random prime-labelled using the Prime-It kit (Stragagene; Catalog No. 300392). The hybridization is carried out in Amersham Rapid-hyb buffer according to the manufacturer's recommendations. The filters are then washed in 2 x SSC/1% SDS at 65°C and exposed to Kodak film at -80°C.
10 Grid positions of positive PAC clones are identified, and the corresponding clones can be obtained from Genome Systems, Inc. The genomic clones are important for designing diagnostic reagents, e.g., by providing intron/exon boundaries.

- 34 -

TABLE 1

Differentially Expressed and Pathway Genes

Gene	SEQ ID NOS	Higher Expression In	Chromosome	RT-PCR	Database Hits	Fig. Nos.
030	1	N	nd	+	human MAL	1a
036, 095	2 4 6	N	4	(11/12)	EST B4E07	1b 1d 2
056	3	N	(10)	(8/8)	human calcium activated potassium channel mRNA hSlo	1c
097	5	T	nd	(10/12)	human translationally controlled tumor protein	1e

In cases where the differentially expressed or pathway gene identified is a normal, or wild type, gene, this gene can be used to isolate mutant alleles of the gene. Such an isolation is preferable in processes and disorders which are known or suspected of having a genetic basis. Mutant alleles can be isolated from individuals either known or suspected of having a genotype that contributes to tumor or cancer symptoms. Mutant alleles and mutant allele products can then be used in the therapeutic and diagnostic assay systems described below.

A cDNA of a mutant gene can be isolated, for example, by using PCR. In this case, the first cDNA strand can be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue, e.g., colon tissue, in an individual known or suspected of carrying the mutant allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA can then be synthesized using an oligonucleotide that hybridizes specifically to the 5'- end of the normal gene. Using these two primers, the product is then

- 35 -

amplified via PCR, cloned into a suitable vector, and subjected to DNA sequence analysis through methods well-known to one skilled in the art. By comparing the DNA sequence of the mutant gene to that of the normal gene, the mutation(s) responsible for the loss or alteration of function of the mutant gene product can be determined.

Alternatively, a genomic or cDNA library can be constructed and screened using DNA or RNA, respectively, from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele. The normal gene or any suitable fragment thereof can then be labeled and used as a probe to identify the corresponding mutant allele in the library. The clone containing this gene can then be purified through routine methods and subjected to sequence analysis as described in this Section.

Additionally, an expression library can be constructed utilizing DNA isolated from or cDNA synthesized from a tissue known to express, or suspected of expressing, the gene of interest in an individual suspected of carrying, or known to carry, the mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal gene product as described below (for screening techniques, see, for example, Harlow et al. (eds.), Antibodies: A Laboratory Manual, (Cold Spring Harbor Press, Cold Spring Harbor, 1988)).

In cases where the mutation results in an expressed gene product with altered function, e.g., as a result of a missense mutation, a polyclonal set of antibodies is likely to cross-react with the mutant gene product. Library clones detected via their reaction with

- 36 -

such labeled antibodies can be purified and subjected to sequence analysis as described in this Section.

4.5. Differentially Expressed and Pathway Gene Products

Differentially expressed and pathway gene products
5 include those peptides encoded by the differentially
expressed and pathway gene sequences described in Section
4.2.1, above. Specifically, differentially expressed and
pathway gene products can include differentially
expressed and pathway gene polypeptides encoded by the
10 differentially expressed and pathway gene sequences
contained in the coding regions of the genes
corresponding to the DNA sequences in Figs. 1a through 1e
and Fig. 2.

In addition, differentially expressed and pathway
15 gene products can include peptides and proteins that
represent functionally equivalent gene products. Such an
equivalent gene products can contain deletions,
additions, or substitutions of amino acid residues, but
which result in a silent change, thus producing a
20 functionally equivalent product. Amino acid
substitutions can be made on the basis of similarity in
polarity, charge, solubility, hydrophobicity,
hydrophilicity, and/or the amphipatic nature of the
residues involved.

25 For example, nonpolar (hydrophobic) amino acids
include alanine, leucine, isoleucine, valine, proline,
phenylalanine, tryptophan, and methionine; polar neutral
amino acids include glycine, serine, threonine, cysteine,
tyrosine, asparagine, and glutamine; positively charged
30 (basic) amino acids include arginine, lysine, and
histidine; and negatively charged (acidic) amino acids
include aspartic acid and glutamic acid. "Functionally
equivalent," as used herein, refers to either a peptide
that exhibits a substantially similar in vivo activity as

- 37 -

the endogenous differentially expressed or pathway gene products encoded by the differentially expressed or pathway gene sequences described in Section 4.2.1, above. Alternatively, when used as part of assays such as those described, herein, "functionally equivalent" can refer to peptides capable of interacting with other cellular or extracellular molecules in a manner substantially similar to the way in which the corresponding portion of the endogenous differentially expressed or pathway gene product would.

The differentially expressed or pathway gene products can be produced by synthetic techniques or via standard recombinant DNA technology. Methods for preparing the differentially expressed or pathway gene peptides of the invention by expressing nucleic acid encoding differentially expressed or pathway gene sequences are described herein. Methods well known to those skilled in the art can be used to construct expression vectors containing differentially expressed or pathway gene protein coding sequences and appropriate transcriptional/translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo recombination/ genetic recombination. See, for example, the techniques described in Maniatis et al., Molecular Cloning A Laboratory Manual (Cold Spring Harbor Laboratory, N.Y., 1989), and Ausubel, 1989, supra. Alternatively, RNA capable of encoding differentially expressed or pathway gene protein sequences can be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in Gait, M.J. ed., Oligonucleotide Synthesis, (IRL Press, Oxford, 1984).

A variety of host-expression vector systems can be used to express the differentially expressed or pathway

- 38 -

gene coding sequences of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest can be produced and subsequently purified, but also represent cells that can, when

5 transformed or transfected with the appropriate nucleotide coding sequences, exhibit the differentially expressed or pathway gene protein of the invention in situ. These include, but are not limited to, microorganisms such as bacteria, e.g., *E. coli* or, *B.*

10 *subtilis*, transformed with recombinant bacteriophage DNA, plasmid or cosmid DNA expression vectors containing differentially expressed or pathway gene protein coding sequences; yeast, e.g., *Saccharomyces* or *Pichia*, transformed with recombinant yeast expression vectors

15 containing the differentially expressed or pathway gene protein coding sequences; insect cell systems infected with recombinant virus expression vectors, e.g., baculovirus, containing the differentially expressed or pathway gene protein coding sequences; plant cell systems

20 infected with recombinant virus expression vectors, e.g., cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV), or transformed with recombinant plasmid expression vectors, e.g., Ti plasmids, containing differentially expressed or pathway gene protein coding sequences; or

25 mammalian cell systems, e.g., COS, CHO, BHK, 293 or 3T3, harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells, e.g., metallothionein promoter, or from mammalian viruses, e.g., the adenovirus late promoter or the

30 vaccinia virus 7.5K promoter.

When used as a component in assay systems such as those described herein, the differentially expressed or pathway gene protein can be labeled, either directly or indirectly, to facilitate detection of a complex formed

35 between the differentially expressed or pathway gene

- 39 -

protein and a test substance. Any of a variety of suitable labeling systems can be used including but not limited to radioisotopes such as ^{125}I ; enzyme labelling systems that generate a detectable colorimetric signal or
5 light when exposed to substrate; and fluorescent labels.

Where recombinant DNA technology is used to produce the differentially expressed or pathway gene protein for such assay systems, it can be advantageous to engineer fusion proteins that can facilitate labeling,
10 solubility, immobilization, and/or detection.

Indirect labeling involves the use of a third protein, such as a labeled antibody, which specifically binds to either a differentially expressed or pathway gene product. Such antibodies include but are not
15 limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library.

4.6. Antibodies Specific for Differentially Expressed or Pathway Gene Products

20 Antibodies that specifically bind to one or more differentially expressed or pathway gene epitopes can be produced by a variety of methods. Such antibodies can include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric
25 antibodies, single chain antibodies, Fab fragments, F(ab')_2 fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

Such antibodies can be used, for example, in the
30 detection of a fingerprint, target, or pathway gene in a biological sample, or, alternatively, in a method for the inhibition of abnormal target gene activity. Thus, such antibodies can be used in treatment methods for tumors and cancers (e.g., colon cancer), and/or in diagnostic
35 methods whereby patients can be tested for abnormal

- 40 -

levels of fingerprint, target, or pathway gene proteins, or for the presence of abnormal forms of such proteins.

To produce antibodies to a differentially expressed or pathway gene protein, a host animal is
5 immunized with the protein, or a portion thereof. Such host animals can include but are not limited to rabbits, mice, and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's
10 (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), and potentially useful human adjuvants such as BCG
15 (bacille Calmette-Guerin) and *Corynebacterium parvum*.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines
20 in culture. These include, but are not limited to the hybridoma technique of Kohler and Milstein, (Nature, 256:495-497, 1975; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., Immunology Today, 4:72, 1983; Cole et al., Proc. Natl. Acad. Sci. USA, 80:2026-2030, 1983), and the BV-hybridoma
25 technique (Cole et al., Monoclonal Antibodies And Cancer Therapy (Alan R. Liss, Inc. 1985), pp. 77-96. Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The
30 hybridoma producing the mAb of this invention can be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

In addition, techniques developed for the
35 production of "chimeric antibodies" can be made by

- 41 -

splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity (see, Morrison et al., Proc. Natl. Acad. Sci., 5 81:6851-6855, 1984; Neuberger et al., Nature, 312:604-608, 1984; Takeda et al., Nature, 314:452-454, 1985; and U.S. Patent No. 4,816,567). A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable
10 region derived from a murine mAb and a constant region derived from human immunoglobulin.

Alternatively, techniques described for the production of single chain antibodies (e.g., U.S. Patent 4,946,778; Bird, Science, 242:423-426, 1988; Huston et
15 al., Proc. Natl. Acad. Sci. USA, 85:5879-5883, 1988; and Ward et al., Nature, 334:544-546, 1989), and for making humanized monoclonal antibodies (U.S. Patent No. 5,225,539), can be used to produce anti-differentially expressed or anti-pathway gene product antibodies.

20 Antibody fragments that recognize specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab'), fragments that can be produced by pepsin digestion of the antibody molecule, and the Fab fragments
25 that can be generated by reducing the disulfide bridges of the F(ab'), fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., Science, 246:1275-1281, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the
30 desired specificity.

4.7. Cell- and Animal-Based Model Systems

Cell- and animal-based model systems for tumors and cancers (e.g., colon cancer) can be used to identify differentially expressed genes via the paradigms

- 42 -

described in Section 4.1.1. Such systems can also be used to further characterize differentially expressed and pathway genes as described in Section 4.3. In addition, an unknown compound's ability to ameliorate symptoms in these models can be used to identify drugs, pharmaceuticals, therapies, and interventions effective in treating tumors and cancers. Animal models also can be used to determine the LD₅₀ and the ED₅₀ of a compound, and such data can be used to determine the in vivo efficacy of potential anti-colon tumor or cancer treatments.

4.7.1. Animal Models

Animal models of tumors and cancers (e.g., colon cancer) include both non-recombinant as well as recombinantly engineered transgenic animals. Non-recombinant animal models for cancer include, for example, murine models. Such models can be generated, for example, by introducing tumor cells into syngeneic mice using techniques such as subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under the renal capsule, or orthotopic implantation, e.g., colon cancer cells implanted in colonic tissue. See the discussion of the METAMOUSE™ above. After an appropriate period of time, the tumors resulting from these injections can be counted and analyzed. Cells that can be used in such animal models are cells derived from tumors and cancers (e.g., colon cancer), or cell lines such as Caco-2 or HT-29.

The role of identified gene products, e.g., encoded by genes described herein, can be determined by transfecting cDNAs encoding such gene products into the appropriate cell line and analyzing its effect on the cells' ability to induce tumors and cancers in an animal model. The role of the identified gene products can be

- 43 -

further analyzed by culturing cells derived from the tumors which develop in the animal models, introducing these cultured cells into animals, and subsequently measuring the level of identified gene product present in the resulting tumor cells. In this manner, cell line variants are developed that can be used in analyzing the role of quantitative and/or qualitative differences in the expression of the identified genes on the cells' ability to induce tumors and cancers.

10 Additionally, recombinant animal models exhibiting tumor and cancer characteristics and/or symptoms, can be engineered by using, for example, target gene sequences such as those described in Section 4.4, in conjunction with standard techniques for producing transgenic
15 animals. For example, target gene sequences are introduced into, and overexpressed in, the genome of the animal of interest, or, if endogenous target gene sequences are present, they are either overexpressed or, alternatively, are disrupted to underexpress or
20 inactivate target gene expression.

To overexpress a target gene sequence, the coding portion of the target gene sequence can be ligated to a regulatory sequence which can drive gene expression in the animal and cell type of interest. Such regulatory
25 regions are well known to those of skill in the art.

To underexpress an endogenous target gene sequence, such a sequence can be introduced into the genome of the animal of interest such that the endogenous target gene alleles will be inactivated. Preferably, an
30 engineered sequence including at least part of the target gene sequence is used and introduced, via gene targeting, such that the endogenous target sequence is disrupted upon integration of the engineered target gene sequence into the animal's genome. Gene targeting is discussed
35 below.

- 44 -

Animals of many species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees, can be used to generate animal
5 models of tumors and cancers (e.g., colon, liver, stomach, or lung cancer).

Techniques known in the art can be used to introduce a target gene transgene into animals to produce the founder lines of transgenic animals. Such techniques
10 include, but are not limited to, pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., U.S. Pat. No. 4,873,191, 1989); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA, 82:6148-6152, 1985); gene targeting in
15 embryonic stem cells (Thompson et al., Cell, 56:313-321, 1989); electroporation of embryos (Lo, Mol. Cell. Biol., 3:1803-1814, 1983); and sperm-mediated gene transfer (Lavitrano et al., Cell, 57:717-723, 1989). For a review of such techniques, see, e.g., Gordon, Transgenic
20 Animals, Intl. Rev. Cytol., 115:171-229, 1989. See also Leder et al., U.S. Patent No. 4,736,866 (Transgenic Non-Human Mammal).

The present invention includes transgenic animals that carry the transgene in all their cells, as well as
25 animals that carry the transgene in some, but not all their cells, i.e., mosaic animals. The transgene can be integrated, either as a single transgene or in concatamers, e.g., head-to-head or head-to-tail tandems. The transgene can also be selectively introduced into and
30 activated in a particular cell type by following, for example, the technique of Lasko et al. Proc. Natl. Acad. Sci. USA, 89:6232-6236, 1992. The regulatory sequences required for such a cell type-specific activation depend upon the particular cell type of interest.

- 45 -

When it is desired that the target gene transgene be integrated into the chromosomal site of the endogenous target gene, gene targeting is preferred. Briefly, for this technique, vectors containing some nucleotide
5 sequences homologous to the endogenous target gene of interest are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of, the nucleotide sequence of the endogenous target gene. The transgene can also be
10 selectively introduced into a particular cell type, thus inactivating the endogenous gene of interest in only that cell type, by following, for example, the techniques of Gu et al., Science, 265:103-106, 1994). The regulatory sequences required for such a cell type-specific
15 inactivation depend upon the particular cell type of interest, and are apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant target gene and protein can be assayed by standard techniques. Initial screening can
20 be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals can also be assessed using techniques
25 such as Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and RT-coupled PCR. Samples of target gene-expressing tissue can also be evaluated immunocytochemically using antibodies specific for the transgenic product of
30 interest.

The target gene transgenic animals that express target gene mRNA or target gene transgene peptide (detected immunocytochemically, using antibodies directed against target gene product epitopes) at easily
35 detectable levels should then be further evaluated to

- 46 -

identify those animals which display tumor or cancer characteristics. For example, colon tumor characteristics and/or symptoms can include, for example, those associated with the progressive formation of
5 intestinal polyps, adenomas, adenocarcinoma, and metastatic lesions.

4.7.2. Cell-Based Systems

Cells that contain and express target gene sequences that encode target gene peptides and exhibit
10 cellular phenotypes associated with tumors and cancers (e.g., colon cancer) can be used to identify compounds that prevent and/or ameliorate tumors and cancers. Further, the fingerprint pattern of gene expression of cells of interest can be analyzed and compared to the
15 normal fingerprint pattern. Those compounds that cause cells exhibiting cellular phenotypes of tumors and cancers to produce a fingerprint pattern more closely resembling a normal fingerprint pattern for the cell of interest are considered candidates for further testing.

20 Cells for such assays can include non-recombinant colon cell lines, such as, but not limited to, human colon adenocarcinoma cell lines Caco-2 and HT29. In addition, purified primary or secondary tumor cells derived from either transgenic or non-transgenic tumor
25 cells can be used.

Further, cells for such assays can also include recombinant, transgenic cell lines. For example, the tumor or cancer animal models of the invention can be used to generate cell lines, containing one or more cell
30 types involved in tumors or cancers, that can be used as cell culture models for this disorder. While primary cultures derived from tumors or cancers in transgenic animals of the invention can be used, the generation of continuous cell lines is preferred. For examples of
35 techniques that can be used to derive a continuous cell

- 47 -

line from a transgenic animal, see Small et al., Mol. Cell Biol., 5:642-648, 1985.

Alternatively, cells of a cell type known to be involved in a particular tumor or cancer can be
5 transfected with sequences that increase or decrease the amount of target gene expression within the cell. For example, target gene sequences can be introduced into, and overexpressed in, the genome of the cell of interest, or, if endogenous target gene sequences are present, they
10 can either be overexpressed or, alternatively, be disrupted to underexpress or inactivate target gene expression. These techniques are well known in the art and are discussed above.

Transfection of target gene sequence nucleic acid
15 also can be accomplished by standard techniques. See, for example, Ausubel, 1989, supra. Transfected cells should be evaluated for the presence of the recombinant target gene sequences, for expression and accumulation of target gene mRNA, and for the presence of recombinant
20 target gene protein production. When a decrease in target gene expression is desired, standard techniques can be used to demonstrate whether a decrease in endogenous target gene expression and/or in target gene product production is achieved.

25 4.8. Screening Assays for Compounds that Interact with the Target Gene Product

The following assays are designed to identify compounds that bind to target gene products or to cellular proteins that interact with a target gene
30 product, and compounds that interfere with the interaction of the target gene product with other cellular proteins.

Specifically, such compounds can include, but are not limited to, peptides, such as, soluble peptides,
35 e.g., Ig-tailed fusion peptides, comprising extracellular

- 48 -

portions of target gene product transmembrane receptors, and members of random peptide libraries (see, e.g., Lam et al., Nature, 354:82-84, 1991; Houghton et al., Nature, 354:84-86, 1991), made of D-and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate phosphopeptide libraries; see, e.g., Songyang et al., Cell, 72:767-778, 1993), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')₂, and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

4.8.1. In Vitro Screening Assays for Compounds
That Specifically Bind to a Target Gene Product

In vitro assay systems can identify compounds that specifically bind to the target gene products of the invention. The assays all involve the preparation of a reaction mixture of a target gene protein and a test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method involves anchoring target gene product or the test substance to a solid phase, and detecting target gene product/test compound complexes anchored to the solid phase at the end of the reaction. In one embodiment of such a method, the target gene product can be anchored onto a solid surface, and the test compound, which is not anchored, can be labeled, either directly or indirectly.

In practice, microtiter plates can be used as the solid phase. The anchored component can be immobilized by non-covalent or covalent attachments. Non-covalent

- 49 -

attachment can be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein to be
5 immobilized can be used to anchor the protein to the solid surface. The surfaces can be prepared in advance and stored.

To conduct the assay, the non-immobilized component is added to the coated surface containing the
10 anchored component. After the reaction is complete, unreacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. Where the previously immobilized component is pre-labeled, the detection of label immobilized on the
15 surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the immobilized component (the antibody, in
20 turn, can be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, the reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected, e.g., using
25 an immobilized antibody specific for a target gene or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

30 4.8.2. Assays for Cellular Proteins that
Interact with the Target Gene Products

. Any method suitable for detecting protein-protein interactions can be used to identify novel target product-cellular or extracellular protein interactions. These methods are outlined in Section 4.1.3., supra, for
35 the identification of pathway genes, and can be used to identify proteins that interact with target proteins. In

- 50 -

such a case, the target gene serves as the known "bait" gene.

4.8.3. Assays for Compounds that Interfere
with Gene/Cellular Product Interactions

5 The target gene products of the invention can interact in vivo with one or more cellular or extracellular macromolecules, such as proteins and nucleic acid molecules. Such cellular and extracellular macromolecules are referred to herein as "binding
10 partners." Compounds that disrupt such interactions can be used to regulate the activity of the target gene product, especially mutant target gene products. Such compounds can include, but are not limited to, molecules such as antibodies and peptides.

15 The assay systems all involve the preparation of a reaction mixture containing the target gene product, and the binding partner under conditions and for a time sufficient to allow the two products to interact and bind, thus forming a complex. To test a compound for
20 inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of a target gene product and its cellular or
25 extracellular binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of complexes between the target gene product and the cellular or extracellular binding partner is then detected. The formation of a complex in
30 the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the target gene product and the interactive binding partner.
Additionally, complex formation within reaction mixtures
35 containing the test compound and normal target gene product can also be compared to complex formation within

- 51 -

reaction mixtures containing the test compound and mutant target gene product. This comparison can be important in those cases in which it is desirable to identify compounds that disrupt interactions of mutant but not
5 normal target gene products.

The assays can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the target gene product or the binding partner to a solid phase and detecting complexes anchored
10 to the solid phase at the end of the reaction, as described above. In homogeneous assays, the entire reaction is carried out in a liquid phase, as described below. In either approach, the order of addition of reactants can be varied to obtain different information
15 about the compounds being tested.

For example, test compounds that interfere with the interaction between the target gene products and the binding partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test
20 substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the target gene product and interactive cellular or extracellular binding partner. Alternatively, test compounds that disrupt preformed complexes, e.g.,
25 compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed.

In a homogeneous assay, a preformed complex of the
30 target gene product and the interactive cellular or extracellular binding partner product is prepared in which either the target gene products or their binding partners are labeled, but the signal generated by the label is quenched due to complex formation (see, e.g.,
35 Rubenstein, U.S. Patent No. 4,109,496, which uses this

- 52 -

approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way,
5 test substances that disrupt target gene product/cellular or extracellular binding partner interactions can be identified.

In a particular embodiment, the target gene product can be prepared for immobilization using
10 recombinant DNA techniques described above. For example, the target gene coding region can be fused to a glutathione-S-transferase (GST) gene using a fusion vector such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion
15 product. The interactive cellular or extracellular product is purified and used to raise a monoclonal antibody, using methods routinely practiced in the art. This antibody can be labeled with the radioactive isotope ^{125}I , for example, by methods routinely practiced in the
20 art.

In a heterogeneous assay, the GST-Target gene fusion product is anchored, e.g., to glutathione-agarose beads. The interactive cellular or extracellular binding partner is then added in the presence or absence of the
25 test compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material is washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The
30 interaction between the target gene product and the interactive cellular or extracellular binding partner is detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test

- 53 -

compound will result in a decrease in measured radioactivity.

Alternatively, the GST-target gene fusion product and the interactive cellular or extracellular binding partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound is added either during or after the binding partners are allowed to interact. This mixture is then added to the glutathione-agarose beads and unbound material is washed away. Again, the extent of inhibition of the binding partner interaction can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

In another embodiment of the invention, these same techniques are employed using peptide fragments that correspond to the binding domains of the target gene product and the interactive cellular or extracellular binding partner (where the binding partner is a product), in place of one or both of the full-length products. Any number of methods routinely practiced in the art can be used to identify and isolate the protein's binding site. These methods include, but are not limited to, mutagenesis of one of the genes encoding one of the products and screening for disruption of binding in a co-immunoprecipitation assay.

In addition, compensating mutations in the gene encoding the second species in the complex can be selected. Sequence analysis of the genes encoding the respective products will reveal mutations that correspond to the region of the product involved in interactive binding. Alternatively, one product can be anchored to a solid surface using methods described above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a short, labeled peptide

- 54 -

comprising the binding domain can remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the cellular or extracellular binding partner product is obtained, short gene segments can be engineered to express peptide fragments of the product, which can then be tested for binding activity and purified or synthesized.

10 4.8.4. Assays for Amelioration
 of Colon Cancer Symptoms

Any of the binding compounds, e.g., those identified in the foregoing assay systems, can be tested for the ability to prevent and/or ameliorate symptoms of tumors and cancers (e.g., colon cancer). Cell-based and animal model-based assays for the identification of compounds exhibiting an ability to prevent and/or ameliorate tumors and cancers symptoms are described below.

First, cell-based systems such as those described in Section 4.7.2, can be used to identify compounds that ameliorate symptoms of tumors and cancers. For example, such cell systems can be exposed to a compound suspected of ameliorating colon tumor or cancer symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration in the exposed cells. After exposure, the cells are examined to determine whether one or more tumor or cancer phenotypes has been altered to resemble a more normal or more wild-type, non-cancerous phenotype.

For colon cancer, cell-based systems using the Caco-2 and HT-29 cell lines can be used. Upon exposure to such cell systems, compounds can be assayed for their ability to reduce the cancerous potential of such cells. Further, the level of all gene expression within these cells may be assayed. Presumably, an increase in the observed level of expression of genes 30, 36 (095), and

- 55 -

56, and a decrease in the level of expression of genes 97, would indicate an amelioration of tumors and cancers (e.g., colon cancer).

In addition, animal models, such as those
5 described, above, in Section 4.7.1, can be used to identify compounds capable of ameliorating symptoms of tumors and cancers. Such animal models can be used as test substrates for the identification of drugs, pharmaceuticals, and therapies which can be effective in
10 treating tumors and cancers. For example, animal models can be exposed to a compound suspected of exhibiting an ability to ameliorate tumor or cancer symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration in the exposed animals. The
15 response of the animals to the exposure can be monitored by assessing the reversal of disorders associated with the tumor or cancer. Any treatments which reverse any symptom of tumors and cancers should be considered as candidates for human therapy. Dosages of test agents can
20 be determined by deriving dose-response curves, as discussed in Section 4.10.

Fingerprint patterns can be characterized for known cell states, e.g., normal or known pre-neoplastic (e.g., polyps), neoplastic (e.g., adenomas or
25 adenocarcinomas), or metastatic states, within the cell- and/or animal-based model systems. Subsequently, these known fingerprint patterns can be compared to ascertain the effect a test compound has to modify such fingerprint patterns, and to cause the pattern to more closely
30 resemble that of a normal fingerprint pattern.

For example, administration of a compound can cause the fingerprint pattern of a cancerous model system to more closely resemble a control, normal system. Administration of a compound can, alternatively, cause

- 56 -

the fingerprint pattern of a control system to begin to mimic tumors and cancers (e.g., colon cancer).

4.8.5. Monitoring of Effects During Clinical Trials

5 The influence of compounds on tumors and cancers can be monitored not only in basic drug screening, but also in clinical trials. In such clinical trials, the expression of a panel of genes that has been discovered in any one of the paradigms of Section 4.1.1 can be used
10 as a "read out" of the tumor or cancer state of a particular cell.

For example, in a clinical trial, tumor cells can be isolated from colon tumors removed by surgery, and RNA prepared and analyzed by Northern blot analysis or RT-PCR
15 as described herein, or alternatively by measuring the amount of protein produced. In this way, the fingerprint profiles can serve as putative biomarkers indicative of colon tumors or cancers. Thus, by monitoring the level of expression of the differentially expressed genes
20 described herein, a protocol for suitable chemotherapeutic anticancer drugs can be developed.

4.9. Compounds and Methods for Treatment of Tumors

Symptoms of tumors and cancers can be ameliorated by, e.g., target gene modulation, and/or by a depletion
25 of the cancerous cells. Target gene modulation can be of a positive or negative nature, depending on the specific situation involved, but each modulatory event yields a net result in which tumor and cancer (e.g., colon cancer) symptoms are ameliorated.

30 "Negative modulation," as used herein, refers to a reduction in the level and/or activity of target gene product relative to the level and/or activity of the target gene product in the absence of the modulatory treatment. "Positive modulation," as used herein, refers
35 to an increase in the level and/or activity of target

- 57 -

gene product relative to the level and/or activity of target gene product in the absence of modulatory treatment.

It is possible that tumors and cancers can be brought about, at least in part, by an abnormal level of gene product, or by the presence of a gene product exhibiting abnormal activity. As such, the reduction in the level and/or activity of such gene products would bring about the amelioration of tumor and cancer symptoms. For example, an increase in the level of expression of gene numbers 048, 083, 090, 093 and 097 correlates with tumors and cancers (e.g., colon cancer). Therefore, a negative modulatory technique that decreases the expression of these genes in tumors and cancers (e.g., colon cancer) should result in a decrease in cancer symptoms.

Alternatively, it is possible that tumors and cancers can be brought about, at least in part, by the absence or reduction of the level of gene expression, or a reduction in the level of a gene product's activity. As such, an increase in the level of gene expression and/or the activity of such gene products would bring about the amelioration of tumors and cancers symptoms. For example, as demonstrated in the Examples presented below, a reduction in the level of expression of gene numbers 030, 036 (095), and 056 correlates with tumors and cancers (e.g., colon cancer). A positive modulatory technique that increases expression of these genes in tumor and cancer cells should, therefore, act to ameliorate the cancer symptoms.

4.9.1. Negative Modulatory Techniques

As discussed above, tumors and cancers can be treated by techniques that inhibit the expression or activity of target gene products. For example, compounds that exhibit negative modulatory activity can be used in

- 58 -

accordance with the invention to prevent and/or ameliorate symptoms of tumors and cancers (e.g., colon cancer). Such molecules can include, but are not limited to peptides, phosphopeptides, small organic or inorganic
5 molecules, or antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')₂, and FAb expression library fragments, and epitope-binding fragments thereof).

10 Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be used in
15 reducing the level of target gene activity.

4.9.1.1. Negative Modulatory Antisense, Ribozyme and Triple Helix

Approaches

Compounds that can prevent and/or ameliorate
20 symptoms of tumors and cancers include antisense, ribozyme, and triple helix molecules. Such molecules can be designed to reduce or inhibit either wild type, or if appropriate, mutant target gene activity. For example, anti-sense RNA and DNA molecules act to directly block
25 the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. With respect to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of
30 interest, are preferred.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. For a review, see, for example, Rossi, Current Biology, 4:469-471 (1994). The mechanism of ribozyme action involves
35 sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by an

- 59 -

endonucleolytic cleavage. A composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include a well-known catalytic sequence responsible for mRNA
5 cleavage. For this sequence, see U.S. Pat. No. 5,093,246, which is incorporated by reference herein in its entirety. As such, the present invention includes engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic
10 cleavage of RNA sequences encoding target gene proteins.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the molecule of interest for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC.
15 Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render an oligonucleotide sequence
20 unsuitable. The suitability of candidate sequences can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

Nucleic acid molecules in triple helix formations
25 used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either
30 purines or pyrimidines on one strand of a duplex. Nucleotide sequences can be pyrimidine-based, which will result in TAT and CGC triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to
35 a purine-rich region of a single strand of the duplex in

- 60 -

a parallel orientation to that strand. In addition, nucleic acid molecules can be chosen that are purine-rich, for example, contain a stretch of G residues. These molecules will form a triple helix with a DNA

5 duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.

Alternatively, the potential sequences that can be
10 targeted for triple helix formation can be increased by creating a so called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating
15 the necessity for a sizeable stretch of either purines or pyrimidines on one strand of a duplex.

In instances wherein the antisense, ribozyme, and/or triple helix molecules described herein are used to reduce or inhibit mutant gene expression, it is
20 possible that they can also efficiently reduce or inhibit the transcription (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles such that the concentration of normal target gene product present can be lower than is necessary for a
25 normal phenotype. In such cases, to ensure that substantially normal levels of target gene activity are maintained, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene
30 therapy methods such as those described herein that do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being used. Alternatively, when the target gene encodes an extracellular protein, it may be preferable to
35 coadminister normal target gene protein into the cell or

- 61 -

tissue to maintain the requisite level of cellular or tissue target gene activity.

Anti-sense RNA and DNA, ribozyme, and triple helix molecules of the invention can be prepared by standard methods known in the art for the synthesis of DNA and RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as, for example, solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules can be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors which also include suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

Various well-known modifications to the DNA molecules can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of ribo- or deoxy-nucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

4.9.1.2. Negative Modulatory Antibody Techniques

Antibodies can be generated which are both specific for a target gene product and which reduce target gene product activity. Therefore, such antibodies can be administered when negative modulatory techniques are appropriate for the treatment of tumors and cancers (e.g., colon cancer). Antibodies can be generated using standard techniques described in Section 4.6, against the

- 62 -

proteins themselves or against peptides corresponding to portions of the proteins.

In instances where the target gene protein to which the antibody is directed is intracellular, and whole antibodies are used, internalizing antibodies are preferred. However, lipofectin or liposomes can be used to deliver the antibody, or a fragment of the Fab region which binds to the target gene epitope, into cells. Where fragments of an antibody are used, the smallest inhibitory fragment which specifically binds to the target protein's binding domain is preferred. For example, peptides having an amino acid sequence corresponding to the domain of the variable region of the antibody that specifically binds to the target gene protein can be used. Such peptides can be synthesized chemically or produced by recombinant DNA technology using methods well known in the art (e.g., see Creighton, 1983, supra; and Sambrook et al., 1989, supra).

Alternatively, single chain neutralizing antibodies that bind to intracellular target gene product epitopes can also be administered. Such single chain antibodies can be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell population by using, for example, techniques such as those described in Marasco et al. Proc. Natl. Acad. Sci. USA, 90:7889-7893 (1993).

When the target gene protein is extracellular, or is a transmembrane protein, any of the administration techniques described in Section 4.10 which are appropriate for peptide administration can be used to effectively administer inhibitory target gene antibodies to their site of action.

4.9.2. Positive Modulatory Techniques

- 63 -

As discussed above, tumor and cancer symptoms also can be treated by increasing the level of target gene expression or by increasing the activity of a target gene product. For example, a target gene protein can be
5 administered to a patient at a level sufficient to ameliorate tumor and cancer (e.g., lung or colon cancer) symptoms. Any of the techniques discussed in Section 4.10, can be used for such administration. One of skill in the art will know how to determine the concentration
10 of effective, non-toxic doses of the normal target gene protein, using techniques such as those described in Section 4.10.1.

Where the compound to be administered is a peptide, DNA sequences encoding the peptide can,
15 alternatively, be directly administered to a patient exhibiting tumor or cancer symptoms, at a concentration sufficient to generate the production of an amount of target gene product adequate to ameliorate the tumor or cancer symptoms. Any techniques that achieve
20 intracellular administration can be used for the administration of such DNA molecules.

DNA molecules that encode peptides that act extracellularly can be taken up and expressed by any cell type, so long as a sufficient circulating concentration
25 of peptide results in a reduction in tumor or cancer symptoms. DNA molecules that encode peptides that act intracellularly must be taken up and expressed by cells involved in the tumors and cancers at a sufficient level to bring about the reduction of tumor or cancer symptoms.

30 Further, patients can be treated for symptoms of tumors or cancers by gene replacement therapy. One or more copies of a normal target gene, or a portion of the gene that directs the production of a normal target gene protein with target gene function, can be inserted into
35 cells, using vectors that include, but are not limited

- 64 -

to, adenovirus, adeno-associated virus, and retrovirus vectors, in addition to other particles that introduce DNA into cells, such as liposomes. Techniques such as those described above can be utilized for the

5 introduction of normal target gene sequences into human cells.

In instances wherein the target gene encodes an extracellular, secreted gene product, such gene replacement techniques may be accomplished either in vivo
10 or in vitro. For such cases, the cell type expressing the target gene is less important than achieving a sufficient circulating concentration of the extracellular molecules to ensure amelioration of tumor and cancer symptoms. In vitro, target gene sequences can be
15 introduced into autologous cells. Those cells expressing the target gene sequence of interest can then be reintroduced, preferably by intravenous administration, into the patient such that there results an amelioration of tumor and cancer symptoms.

20 In instances wherein the gene replacement involves a gene that encodes a product which acts intracellularly, it is preferred that gene replacement be accomplished in vivo. Further, because the cell type in which the gene replacement must occur is the cell type involved in a
25 tumor or cancer, such techniques must successfully target tumor and cancer cells.

Taking the gene 036 as an example, an increase in gene expression can serve to ameliorate tumor and cancer, e.g., colon cancer, symptoms. Therefore, any positive
30 modulation described herein that increases the gene 036 product or gene product activity to a level sufficient to ameliorate tumor and cancer symptoms represents a successful tumor and cancer therapeutic treatment.

- 65 -

4.10. Pharmaceutical Preparations and Methods of Administration

The identified compounds that inhibit target gene expression, synthesis, and/or activity can be

5 administered to a patient at therapeutically effective doses to prevent, treat, or ameliorate a tumor or cancer. A therapeutically effective dose refers to that amount of the compound sufficient to result in a viable or measurable decrease in tumor or cancer symptoms.

10 4.10.1. Effective Dose

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of
15 the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio, LD₅₀/ED₅₀. Compounds that exhibit large therapeutic indices are
20 preferred. While compounds that exhibit toxic side effects can be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue to minimize potential damage to uninfected cells and, thereby, reduce side effects.

25 The data obtained from the cell culture assays and animal studies can be used to formulate a dosage range for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The
30 dosage can vary within this range depending upon the dosage form employed and the route of administration. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in
35 animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (the

- 66 -

concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can
5 be measured, for example, by high performance liquid chromatography.

4.10.2. Formulations and Use

Pharmaceutical compositions for use in the present invention can be formulated by standard techniques using
10 one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates can be formulated for administration by inhalation or insufflation (either through the mouth or the nose, or
15 oral, buccal, parenteral, or rectal administration.

For oral administration, the pharmaceutical compositions can take the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents, e.g.,
20 pregelatinised maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose; fillers, e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate; lubricants, e.g., magnesium stearate, talc, or silica; disintegrants, e.g., potato starch or sodium
25 starch glycolate; or wetting agents, e.g., sodium lauryl sulphate. The tablets can be coated by methods well known in the art.

Liquid preparations for oral administration can take the form of solutions, syrups, or suspensions, or
30 they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, e.g., sorbitol syrup, cellulose
35 derivatives, or hydrogenated edible fats; emulsifying

- 67 -

agents, e.g., lecithin or acacia; non-aqueous vehicles, e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils; and preservatives, e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid. The
5 preparations can also contain buffer salts, flavoring, coloring, and/or sweetening agents as appropriate.

Preparations for oral administration can be suitably formulated to give controlled release of the active compound.

10 For administration by inhalation, the compounds are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
15 dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator can be
20 formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be
25 presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending,
30 stabilizing, and/or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds can also be formulated in rectal
35 compositions such as suppositories or retention enemas,

- 68 -

e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions can, if desired, be presented in a pack or dispenser device which can contain one or more unit dosage forms containing the active ingredient. The pack can for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration.

4.11. Diagnosis of Tumors or Cancers

A variety of methods can be employed to diagnose tumors and cancers, e.g., lung, liver, or colon cancer. Such methods can, for example, use reagents such as fingerprint gene nucleotide sequences or antibodies directed against differentially expressed and pathway gene peptides. Specifically, such reagents can be used for the detection of the presence of target gene mutations, or the detection of either over- or under-expression of a target gene in RNA.

4.11.1. Detection of Fingerprint Gene Nucleic Acids

DNA or RNA from the cell type or tissue to be analyzed can be easily isolated using standard procedures. Diagnostic procedures can also be performed "in situ" directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or

- 69 -

resections, such that no nucleic acid purification is necessary. Nucleic acid reagents such as those described herein can be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, G.J., PCR in situ hybridization: Protocols and Applications, Raven Press, NY, 1992).

Fingerprint gene nucleotide sequences, either RNA or DNA, can, for example, be used in hybridization or amplification assays of biological samples to detect gene structures and expression associated with tumors and cancers, e.g., colon cancer. Such assays can include, but are not limited to, Southern or Northern analyses, single stranded conformational polymorphism analyses, in situ hybridization assays, and polymerase chain reaction analyses. Such analyses can reveal both quantitative aspects of the expression pattern of a fingerprint gene, and qualitative aspects of the fingerprint gene expression and/or gene composition. That is, such techniques can include, for example, point mutations, insertions, deletions, chromosomal rearrangements, and/or activation or inactivation of gene expression.

Preferred diagnostic methods for the detection of fingerprint gene-specific nucleic acid molecules involve contacting and incubating nucleic acids derived from the cell type or tissue being analyzed with one or more labeled nucleic acid reagents, under conditions favorable for the specific annealing of these reagents to their complementary sequences within the nucleic acid molecule of interest. Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid:fingerprint RNA molecule hybrid. The presence of nucleic acids from the target tissue which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the

- 70 -

nucleic acid from the tissue or cell type of interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtitre plate or polystyrene beads. In this case,
5 after incubation, non-annealed, labeled fingerprint nucleic acid reagents are easily removed. Detection of the remaining, annealed, labeled nucleic acid reagents is accomplished using standard techniques.

Alternative diagnostic methods for the detection
10 of fingerprint gene specific nucleic acid molecules can involve their amplification, e.g., by PCR (see Mullis, U.S. Patent No. 4,683,202, 1987), ligase chain reaction (Barany, Proc. Natl. Acad. Sci. USA, 88:189-193, 1991), self-sustained sequence replication (Guatelli et al.,
15 Proc. Natl. Acad. Sci. USA, 87:1874-1878, 1990), transcriptional amplification system (Kwoh et al., Proc. Natl. Acad. Sci. USA, 86:1173-1177, 1989), Q-Beta replicase (Lizardi et al., Bio/Technology, 6:1197, 1988), or any other nucleic acid amplification method, followed
20 by the detection of the amplified molecules using standard techniques. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

25 In one embodiment of such a detection scheme, a cDNA molecule is obtained from an RNA molecule of interest, e.g., by reverse transcription of the RNA molecule into cDNA. Cell types or tissues from which such RNA can be isolated include any tissue in which a
30 wild type fingerprint gene is known to be expressed. A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents, e.g.,
35 primers, in the reverse transcription and nucleic acid

- 71 -

amplification steps of this method are chosen from among the fingerprint gene nucleic acid reagents describe above. The preferred lengths of such nucleic acid reagents are at least 19-30 nucleotides. For detection
5 of the amplified product, the nucleic acid amplification can be performed using labeled nucleotides. Alternatively, enough amplified product can be made such that the product can be visualized by standard ethidium bromide staining or by utilizing any other suitable
10 nucleic acid staining method.

In addition to methods that focus primarily on the detection of one nucleic acid sequence, fingerprint profiles can also be assessed in such detection schemes.

4.11.2. Detection of Target Gene Peptides

15 Antibodies directed against wild type or mutant fingerprint gene peptides can also be used, e.g., in immunoassays, for tumor and cancer diagnostics and prognostics. Such diagnostic methods can be used to detect abnormalities in the level of fingerprint gene
20 protein expression, or abnormalities in the structure and/or tissue, cellular, or subcellular location of fingerprinting gene protein. Structural differences can include, for example, differences in the size, electronegativity, or antigenicity of the mutant
25 fingerprint gene protein relative to the normal fingerprint gene protein.

Protein from the tissue or cell type to be analyzed can easily be isolated using standard techniques, e.g., as described in Harlow and Lane,
30 Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1988).

For example, antibodies, or fragments of antibodies, such as those described herein, can be used to quantitatively or qualitatively detect the presence of

- 72 -

wild type or mutant fingerprint gene peptides. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow
5 cytometric, or fluorimetric detection. Such techniques are especially preferred if the fingerprint gene peptides are expressed on the cell surface.

The antibodies (or fragments thereof) useful in the present invention can, additionally, be employed
10 histologically, as in immunofluorescence or immunoelectron microscopy, for in situ detection of target gene peptides. In situ detection can be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody of the
15 present invention. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the fingerprint gene peptides, but also
20 their distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified to achieve such in situ detection.

25 Immunoassays for wild type or mutant fingerprint gene peptides typically comprise incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells, or cells which have been incubated in tissue culture, in the presence of a
30 detectably labeled antibody capable of identifying fingerprint gene peptides, and detecting the bound antibody by any of a number of techniques well-known in the art.

The biological sample can be brought in contact
35 with and immobilized on a solid phase support or carrier

- 73 -

such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles, or soluble proteins. The support can then be washed with suitable buffers followed by treatment with the detectably labeled fingerprint gene specific antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

- 10 One of the ways in which the fingerprint gene peptide-specific antibody can be detectably labeled is by linking the same to an enzyme, e.g., horseradish peroxidase, alkaline phosphatase, or glucoamylase, and using it in an enzyme immunoassay (EIA) (see, e.g.,
- 15 Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)," Diagnostic Horizons, 2:1-7 (1978); Voller et al., J. Clin. Pathol., 31:507-520 (1978); Butler, J.E., Meth. Enzymol., 73:482-523 (1981); Maggio, E. (ed.), Enzyme Immunoassay (CRC Press, Boca Raton, FL, 1980);
- 20 Ishikawa et al. (eds.), Enzyme Immunoassay (Kagaku Shoin, Tokyo, 1981)). The enzyme bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety that can be detected, for example, by
- 25 spectrophotometric, fluorimetric or by visual means.

5. EXAMPLE

Identification and Characterization of Novel Genes That Inhibit or Induce Tumors or Cancer

- In this Example, the "specimen paradigm" described
- 30 above was used to identify a number of genes, designated herein as numbered genes, that are differentially expressed in colon cancer cells compared to normal colon cells. Specifically, gene number 097 is expressed in colon cancer cells at a rate which is many-fold higher
- 35 than they are expressed in normal colon cells, and gene

- 74 -

numbers 030, 036, 056, and 095 are expressed in normal colon cells at a rate that is many-fold higher than they are expressed in cancerous colon cells. Given the differential gene expression patterns revealed in this
5 Section, the products of this second set of genes represent peptides having tumor suppressor or inhibitor function.

5.1. Materials and Methods

5.1.1. Differential Display

10 Differential mRNA display was carried out as described above. Details of the differential display are given below.

RNA Isolation

Primary colon tumors and adjacent normal colon
15 tissue were obtained as surgical biopsies from twelve independent colon cancer patients. These samples were snap frozen in liquid nitrogen and stored at -80°C until used for RNA extraction. Total RNA was extracted from these samples using RNazol. Isolated RNA was resuspended
20 in DEPC treated dH₂O and quantitated by spectrophotometry at OD₂₆₀. An aliquot of each RNA sample was then treated with RNase-free DNase I to remove contaminating chromosomal DNA. Fifty µg of RNA in 50 µl DEPC-treated dH₂O were mixed with 5.7 µl 10 x PCR buffer
25 (Perkin-Elmer/Cetus) and 1 µl RNase inhibitor (40 units/µl; Boehringer Mannheim, Germany). After addition of 2 µg RNase-free DNase I (10 units/µl; Boehringer Mannheim, Germany), the reaction was incubated for 30 minutes at 37°C. The total volume was brought to 200 µl
30 with DEPC-treated dH₂O and extracted once with phenol/chloroform. The treated RNA sample was then precipitated by addition of 20 µl 3M NaOAc, pH 4.8, and 500 µl absolute ETOH, followed by incubation on dry ice for one hour. RNA was collected by centrifugation for 15

- 75 -

minutes and washed once with 75% ETOH. The pellet was dried and resuspended in 50 μ l DEPC treated dH₂O.

First Strand cDNA Synthesis

For each sample, 2 μ g of RNA in a total volume of 5 10 μ l were added to 2 μ l of T11GG 3' primer (10 mM; Operon). The mixture was incubated at 70°C for 10 minutes to denature the RNA and then placed on ice. The following components were added to each denatured RNA/primer sample: 4 μ l 5 x First Strand Buffer 10 (Gibco/BRL, Gaithersburg, MD), 2 μ l 0.1 M DTT (Gibco/BRL), 1 μ l RNase inhibitor (40 units/ μ l; Boehringer Mannheim), 2 μ l 200 mM dNTP mix (diluted from 20 mM stock; Pharmacia), and 1 μ l SuperScript reverse transcriptase (200 units/ μ l; Gibco/BRL). The reactions 15 were gently mixed and incubated for 30 minutes at 42°C, and then 5 minutes at 85°C. Samples were diluted ten-fold in dH₂O before use in PCR.

PCR Reactions

The diluted first strand cDNAs were used as PCR 20 templates for matched pairs of normal and tumor samples from eight independent patients. Specifically, 13 μ l of reaction mix was added to each tube of a 96 well plate on ice. The reaction mix contained 6.4 μ l H₂O, 2 μ l 10x PCR Buffer (Perkin-Elmer), 2 μ l 20 μ M dNTPs, 0.4 μ l ³⁵S dATP 25 (12.5 μ Ci/ μ l; 50 μ Ci total, Dupont/NEN) or 1.0 μ l ³³P dATP (10.0 μ Ci/ μ l; Dupont/NEN), 2 μ l 5' primer OPE4 (5'GTGACATGCC-3'; 10 μ M; Operon), and 0.2 μ l AmpliTaq™ Polymerase (5 units/ μ l; Perkin-Elmer). Next, 2 μ l of 3' primer (T₁₁CC, 10 μ M) were added to the side of each tube, 30 followed by 5 μ l of cDNA, also to the sides of the tubes, which were still on ice. Tubes were capped and mixed, and brought up to 1000 rpm in a centrifuge, then immediately returned to ice. A Perkin-Elmer 9600 or MJ Research PTC-200 thermal cycler was used, and programmed 35 as follows:

- 76 -

	94°C	2 min.	
	*94°C	15 sec.	
	*40°C	2 min.	* = x 40
	*ramp 72°C	1 min.	
5	*72°C	30 sec.	
	72°C	5 min.	
	4°C	hold	

When the thermal cycler initially reached 94°C, the 96 well plate was removed from ice and placed directly into the cycler. Following the amplification reaction, 15 µl of loading dye, containing 80% formamide, 10 mM EDTA, 1 mg/ml xylene cyanole, 1 mg/ml bromphenol blue were added. The loading dye and reaction were mixed, incubated at 85°C for 5 minutes, cooled on ice, centrifuged, and placed on ice. Approximately 4 µl from each tube was loaded onto a pre-run (60 V) 6% denaturing acrylamide gel. The gel was run at approximately 80V until top dye front was about 1 inch from bottom. The gel was transferred to 3MM paper (Whatman Paper, England) and dried under vacuum. Bands were visualized by autoradiography.

These cDNA bands are referred to as RADE bands (for Rapid Analysis Differential Expression) and were analyzed to select cDNAs that were present in colon cancer tissue but not normal colon tissue from the same individual, or in normal colon tissue and not colon cancer tissue from the same individual. cDNA bands that were differentially expressed in at least 4 of the 8 matched normal/tumor pairs (> 50%) were identified for further characterization.

- 77 -

5.1.2. Other TechniquesAmplified cDNA Band Isolation and Amplification

PCR bands determined to be of interest in the differential display analysis were recovered from the gel and reamplified.

Briefly, differentially expressed bands were excised from the dried gel with a razor blade and placed into a microfuge tube with 100 μ l H₂O and heated at 100°C for 5 minutes, vortexed, heated again to 100°C for 5 minutes, and vortexed again. After cooling, 100 μ l H₂O, 20 μ l 3M NaOAc, 1 μ l glycogen (20 mg/ml), and 500 μ l ethanol were added and the sample was precipitated on dry ice. After centrifugation, the pellet was washed and resuspended in 10 μ l H₂O.

DNA isolated from the excised differentially expressed bands were then reamplified by PCR using the following reaction conditions:

	58	μ l	H ₂ O
	10	μ l	10x PCR Buffer (see above)
20	10	μ l	200 μ M dNTPs
	10	μ l	10 μ M 3' primer (see above)
	10	μ l	10 μ M 5' primer (see above)
	1.5	μ l	amplified band
	0.5	μ l	AmpliTaq® polymerase (5 units/ μ l)

PCR conditions were the same as the initial conditions used to generate the original amplified band, as described, above. After reamplification, glycerol loading dyes were added and samples were loaded onto a 2% preparative TAE/Biogel (Bio101, La Jolla, CA) agarose gel and eluted. Bands were then excised from the gel with a razor blade and vortexed for 15 minutes at r.t., and purified using the Mermaid™ kit from Bio101 by adding 3 volumes of Mermaid™ high salt binding solution and 8 μ l of resuspended glassfog in a microfuge tube. Glassfog

- 78 -

was then pelleted, washed 3 times with ethanol wash solution, and then DNA was eluted twice in 10 μ l at 50°C.

Direct Sequencing of Isolated, Amplified cDNA Bands

Each gel-purified PCR-amplified cDNA band was
5 directly sequenced using the T11GG 3' primer and/or the
arbitrary 10mer 5' primer as sequencing primers with the
fmol sequencing kit (Promega). The sequencing primers
were end labelled by adding 10 pmol of each primer to 1
 μ l of 10x polynucleotide kinase buffer (Promega), 1 μ l of
10 P33- γ -ATP (10mCi/ μ l, NEN), and 1 μ l of polynucleotide
kinase (10 units/ μ l; Promega) in a total volume of 10 μ l.
The reactions were incubated for 30 minutes at 37°C
followed by a 5 minute incubation at 95°C to inactivate
the PNK enzyme. For each sequencing reaction the
15 following components were mixed together: 0.5-1 ng of
isolated, amplified cDNA band, 5 μ l of 5 x fmol buffer
(Promega), 1.5 μ l of end-labeled primer, H₂O to a volume
of 16 μ l, and then 1 μ l of sequencing grade Taq DNA
polymerase (5 units/ μ l; Promega). Four μ l of this
20 sequencing reaction mix were added to each of the four
wells of a microtiter plate containing 2 μ l of ddNTP
termination mix (ddA, ddC, ddG, and ddT; Promega). The
plate of PCR sequencing reactions was briefly centrifuged
at 500 x g to collect the reactions at the bottom of the
25 wells, and then subjected to the following conditions:

	95°C	2 minutes	
	*95°C	30 seconds	* = x 30
	*40°C	1 minute and 30 seconds	
	*70°C	1 minute	
30	4°C	Hold indefinitely	

The reactions were terminated by the addition of 4
 μ l of formamide stop solution (Promega), and denatured by
heating at 80°C for five minutes. The samples were
electrophoresed at 60 Watts on an 8% acrylamide/urea

- 79 -

sequencing gel until the bromophenol blue dye front reached the bottom of the gel. The gel was transferred to 3MM Whatmann Chromatography paper and dried. The dried gel was exposed to X-ray film (Kodak) for 16 hours at room temperature. The sequence was determined by manual reading of the sequencing gel.

Subcloning and Sequencing

The TA cloning kit (Invitrogen, San Diego, CA) was used to subclone the amplified bands. The ligation reaction typically consisted of 4 μ l sterile H₂O, 1 μ l ligation buffer, 2 μ l TA cloning vector, 2 μ l PCR product, and 1 μ l T4 DNA ligase. The volume of PCR product can vary, but the total volume of PCR product plus H₂O was always 6 μ l. Ligations (including vector alone) were incubated overnight at 12°C before bacterial transformation. TA cloning kit competent bacteria (INV α F': endA1, recA1, hsdR17(r-k, m+k), supE44, λ -, thi-1, gyrA, relA1, ϕ 80lacZ α M15 Δ (lacZYA-argF), deoR+, F') were thawed on ice and 2 μ l of 0.5 M β -mercaptoethanol were added to each tube. Two μ l from each ligation were added to each tube of competent cells (50 μ l), mixed without vortexing, and incubated on ice for 30 minutes. Tubes were then placed in 42°C bath for exactly 30 sec., before being returned to ice for 2 minutes. Four hundred-fifty μ l of SOC media (Sambrook et al., 1989, supra) were then added to each tube which were then shaken at 37°C for 1 hour. Bacteria were then pelleted, resuspended in approximately 200 μ l SOC and plated on Luria broth agar plates containing X-gal and 60 μ g/ μ l ampicillin and incubated overnight at 37°C. White colonies were then picked and screened for inserts using PCR.

A master mix containing 2 μ l 10 x PCR buffer, 1.6 μ l 2.5 mM dNTP's, 0.1 μ l 25 mM MgCl₂, 0.2 μ l M13 reverse primer (100 ng/ μ l), 0.2 μ l M13 forward primer (100

- 80 -

ng/ μ l), 0.1 μ l AmpliTaq® (Perkin-Elmer), and 15.8 μ l H₂O was made. Forty μ l of the master mix were aliquoted into tubes of a 96 well plate, and whole bacteria were added with a pipette tip prior to PCR. The thermal cycler was
5 programmed for insert screening as follows:

	94°C	2 min.
	*94°C	15 sec.
	*47°C	2 min. * = x 35
	*ramp 72°C	30 sec.
10	*72°C	30 sec.
	72°C	10 min.
	4°C	hold

Reaction products were eluted on a 2% agarose gel and compared to vector control. Colonies with vectors
15 containing inserts were purified by streaking onto LB/Amp plates. Vectors were isolated from such strains and subjected to sequence analysis, using an Applied Biosystems Automated Sequencer (Applied Biosystems, Inc. Seattle, WA).

20 Northern Analysis

Northern analysis was performed to confirm the differential expression of the genes corresponding to the amplified bands, as described below.

Twelve μ g of total RNA sample, 1.5 x RNA loading
25 dyes (60% formamide, 9% formaldehyde, 1.5 x MOPS, 0.075% XC/BPB dyes) at a final concentration of 1 x and H₂O to a final volume of 40 μ l were mixed. The tubes were heated at 65°C for 5 minutes and then cooled on ice. The RNA samples analyzed were loaded onto a denaturing 1% agarose
30 gel. The gel was run overnight at 32V in 1 x MOPS buffer.

A 300 μ l denaturing 1% agarose gel was made as follows. Three grams of agarose (SeaKem™ LE, FMC

- 81 -

BioProducts, Rockland, ME) and 60 μ l of 5 x MOPS buffer (0.1M MOPS [pH 7.0], 40 mM NaOAc, 5mM EDTA [pH 8.0]) were added to 210 μ l sterile H₂O. The mixture was heated until melted, then cooled to 50°C, at which time 5 μ l ethidium bromide (5mg/ μ l) and 30 μ l of 37% formaldehyde were added to the melted gel mixture. The gel was swirled quickly to mix, and then poured immediately.

After electrophoresis, the gel was photographed with a fluorescent ruler, then was washed three times in DEPC H₂O, for 20 minutes per wash, at room temperature, with shaking. The RNA was then transferred from the gel to Hybond-N[®] membrane (Amersham), according to the methods of Sambrook et al., 1989, supra, in 20 x SSC overnight.

The probes used to detect mRNA were typically synthesized as follows: 2 μ l amplified cDNA band (~30 ng), 7 μ l H₂O, and 2 μ l 10 x Hexanucleotide mix (Boehringer-Mannheim) were mixed and heated to 95°C for 5 minutes, and then allowed to cool on ice. The volume of the amplified band can vary, but the total volume of the band plus H₂O was always 9 μ l. 3 μ l dATP/dGTP/dTTP mix (1:1:1 of 0.5 mM each), 5 μ l α ³²P dCTP 3000 Ci/mM (50 μ Ci total; Amersham, Arlington Heights, IL), and 1 μ l Klenow (2 units; Boehringer-Mannheim) were mixed and incubated at 37°C. After 1 hour, 30 μ l TE were added and the reaction was loaded onto a Biospin-6™ column (Biorad, Hercules, CA), and centrifuged. A 1 μ l aliquot of eluate was used to measure incorporation in a scintillation counter with scintillant to ensure that 10⁶ cpm/ μ l of incorporation was achieved.

For pre-hybridization, the blot was placed into a roller bottle containing 10 ml of rapid-hyb solution (Amersham), and placed into 65°C incubator for at least 1 hour. For hybridization, 1 x 10⁷ cpm of the probe was then heated to 95°C, chilled on ice, and added to 10 ml

- 82 -

of rapid-hyb solution. The prehybridization solution was then replaced with probe solution and incubated for 16 hours at 65°C. The following day, the blot was washed once for 20 minutes at room temperature in 2 x SSC/0.1% SDS and twice for 15 minutes at 65°C in 0.1 x SSC/0.1% SDS before being covered in plastic wrap and put down for exposure.

In other Northern assays, 20 µg of total RNA per sample was run on a 0.9% agarose gel containing 7% formaldehyde. Following electrophoresis, the gel was rinsed in 20 x SSC and then the RNA was transferred to Hybond N+ membrane (Amersham) in 20 x SSC overnight. The filter was prehybridized in 7% SDS, 0.5 M NaHPO₄, 1 mM EDTA, 1% BSA at 65°, then hybridized overnight in the same solution containing 25 ng of probe fragment labeled with the Prime-It Kit (Stratagene) and ³²P α dCTP. The filter was then washed at 65° with three changes of 1% SDS, 40 mM NaHPO₄, 1 mM EDTA, blotted dry, and exposed to Hyperfilm (Amersham) at 80° with intensifying screens.

20 Chromosomal Mapping

DNAs isolated from 24 human/rodent somatic cell hybrids (Coriell Cell Repositories) were used for PCR templates. Each somatic cell hybrid DNA contains one human chromosome, although the entire chromosome may not be represented. A pair of oligonucleotide 20mer primers were generated for each cDNA sequence for use in PCR; those oligonucleotide pairs which could amplify a product of the predicted size from human DNA templates were tested against the somatic cell hybrid DNA panel. Thirty nanograms of each hybrid DNA sample (and parental cell DNA samples) were mixed with 20 pmoles each cDNA specific oligonucleotide primers, 3 µl 10 x PCR buffer (Perkin-Elmer), 2 µl of 2 µM dNTPs (dATP, dCTP, dGTP, dTTP), and 1 µl AmpliTaqTM polymerase (5 units/µl) in a

- 83 -

total volume of 30 μ l. Reactions were subjected to the following conditions:

	95°C	2 min.	
	*95°C	20 sec.	
5	*Tm - 5°C	1 min.	* = x 30 cycles
	*72°C	30 sec.	
	*72°C	5 min.	
	4°C	hold	

and then the products were resolved on 2% agarose gels.

- 10 Primers which gave a band of the correct size in the human DNA control and only one of the hybrid DNA samples was scored as a positive result and the cDNA mapped to the human chromosome contained in that somatic cell hybrid.

15 5.2. Results

- To identify and isolate genes potentially involved in human colorectal carcinoma, differences in gene expression between normal colon cells and colon tumor (adenocarcinomas) cells were examined by differential display. Total RNA was isolated from frozen surgical specimens of normal colons and colon tumors. The RNA samples were treated with RNase-free DNase I, reverse transcribed, and used for differential display analysis as described in Materials and Methods. Matched pairs of normal and tumor samples from eight independent patients were compared. PCR was performed on each cDNA sample using 228 separate arbitrary 10-mer 5' primers in combination with the T11GG 3' primer, and the reaction products were separated on a denaturing sequencing gel and autoradiographed. In a typical comparison of one such primer pair, the eight normal colon PCR samples were run side by side, followed by the eight colon tumor PCR samples. cDNA bands which showed differential expression

- 84 -

in at least 4 of the 8 matched normal/tumor pairs (> 50%) were identified for further characterization.

One hundred and seven separate bands meeting the above criteria were excised and reamplified. The
5 reamplified bands were directly sequenced with the fmol kit; they were also subcloned into the pCRII vector (Invitrogen) and sequenced as described in Materials and Methods. Pairs of oligonucleotide 20mer primers based on
10 the sequence of the cDNAs were generated and used for RT-PCR to confirm the expression pattern seen during differential display. After such analysis, a number of cDNA bands were chosen for further characterization. One sequence appeared twice and was later shown to be part of the same gene (Referred to as gene 036 and described in
15 Section 7.). Thus, 5 separate cDNA sequences and 4 genes are discussed below. The cDNA sequences of the differential display patterns of the RADE bands are presented in Figs. 1a to 1e.

Table 1 shows that one of the cDNA sequences has
20 increased expression in colon tumor RNA samples as compared to normal colon RNA samples, while four sequences were more prominent in normal colon RNA. These tumor-specific genes are potentially useful for diagnostic purposes, and their gene products may be
25 involved in tumor formation or progression, thereby making them potential therapy targets. Loss of gene expression can also lead to carcinogenesis, as has been demonstrated for many tumor suppressor genes. In such cases, replacement of the missing gene product can
30 reverse the transformed phenotype.

Four cDNA sequences corresponding to three genes showed higher expression in normal colon versus colon tumor RNA samples (Table 1), and are therefore candidate tumor suppressor genes. The DNA sequences were further
35 characterized by Northern analysis, mapping to human

- 85 -

chromosomes, and full-length cDNA isolation. The summarized data for each sequence are presented in Table 1.

Table 1 shows summarized data for genes with 5 homologies to known genes, and a gene with a novel sequences. In the table, numbers in parenthesis in the "RT-PCR" column show the number of positive samples, i.e., samples that confirmed the results of the expression pattern in the differential display specimen 10 paradigm, over the number of total samples (8 or 12) assayed. When relevant, the number/name of the human chromosome to which the cDNA band maps is given.

A longer cDNA sequence from gene 036, Fig. 2, described in greater detail in Section 7, was obtained.

15 A BLASTN (Altschul et al., J. Mol. Biol., 215:403-410, 1990) database search was performed with the nucleotide sequences SEQ ID NO:1 (030), SEQ ID NO:3 (056), and SEQ ID NO:2 (036).

Three of the cDNA sequences were identical to 20 known genes (Table 1). SEQ ID NO:1 of gene 030 showed a 99% sequence identity with a portion of the 3' end of the cDNA for human maturation associated lymphocyte (MAL) protein, which is thought to be an integral membrane protein (Alonso et al., Proc. Natl. Acad. Sci., U.S.A., 25 84:1997-2001, 1987) of unknown function. The human MAL protein gene mRNA is shown in Weissman et al., U.S. Patent No. 4,835,255. The nucleotide sequence of the MAL cDNA and the deduced amino acid sequence of the MAL protein are shown in Alonso et al. (1987).

30 SEQ ID NO:3 of gene 056 showed a 99% sequence identity with a coding portion of a human calcium-activated potassium channel mRNA gene, hSlo, located on chromosome 10 (Pallanck et al., Hum. Mol. Genet., 3:1239-1243, 1994), which is normally expressed by smooth

- 86 -

muscle cells and hippocampal cells. The deduced amino acid sequence of hSlo is shown in Pallanck et al. (1994).

Finally, SEQ ID NO:5 of gene 097 showed a 99% sequence identity with a portion of a human mRNA which putatively encodes a translationally controlled tumor protein, by virtue of its homology to a murine gene, growth-related mouse tumor protein p23 (Gross et al., Nucleic Acids Res., 17(20):8367, 1989). Northern analysis of SEQ ID NO:15 expression in normal human colon and human colon tumor samples showed a prominent band of about 1 kb, and a less intense band of about 1.3 kb in size.

Of the remaining cDNA sequences, one, gene 036, is homologous to an EST sequence. SEQ ID NO: 2 of gene 036 showed virtual sequence identity (96%) to the EST clone B4E07, which was isolated from a muscle cDNA library.

6. EXAMPLE

Use of Fingerprint Genes as Surrogate Markers in Clinical Trials

The expression pattern of the fingerprint genes of the invention can be used as surrogate markers to monitor clinical human trials of drugs being tested for their efficacy as tumor or cancer treatments, and can also be used to monitor patients undergoing clinical evaluation for the treatment of tumors and cancers. Either individual "fingerprint gene" expression patterns, or "fingerprint patterns," as defined above, can be analyzed.

The effect of the compound on the fingerprint gene expression normally displayed in connection with tumors and cancers, e.g., colon cancer, can be used to evaluate the efficacy of the compound as a treatment. Additionally, fingerprint gene expression can be used to monitor patients undergoing clinical evaluation for the treatment of tumors or cancers.

- 87 -

According to the invention, any fingerprint gene expression and fingerprint pattern derived from one of the paradigms described in Section 4.1.1. can be used to monitor clinical trials of drugs in human patients. The 5 paradigms described in Section 4.1.1., and illustrated in the Example of Section 5, for example, provide the fingerprint pattern of colon cancer and normal colon cells. This profile gives an indicative reading, therefore, of the cancerous and non-cancerous states of 10 colon cells. Accordingly, the influence of anticancer chemotherapeutic agents on colon cancer cells can be measured by performing differential display on colon cells of patients undergoing clinical tests.

15 6.1. Treatment of Patients and Procurement of Tumor Cells or Biopsies

Compounds suspected of anti-tumor activity are administered to patients, whereas a placebo is administered to control patients. Tumor cells or biopsies are drawn from each patient after a determined 20 period of treatment, e.g., 1 week, and RNA is isolated as described in Section 5.1., above.

6.2. Analysis of Samples

RNA is analyzed by Northern blots and RT-PCT. A decrease in colon cancer symptoms is indicated by an 25 increase in the intensity of the bands corresponding to gene numbers 030, 036, 056, and 095, as described in Section 5.2 above.

7. A NOVEL GENE EXPRESSED AT A HIGHER LEVEL IN NORMAL CELLS THAN IN TUMOR CELLS

30 As noted above, further cloning and sequence analysis demonstrated that the gene 036 (SEQ ID NO: 2) and the gene 095 (SEQ ID NO: 4) are part of the same gene, referred to herein as gene 036. Gene 036 is a

- 88 -

novel gene that is expressed at a higher level in normal cells than in tumor cells. A human MTN Blot (Clontech, Palo Alto, CA; Catalog Nos. 7759-1 and 7760-1) analysis of gene 036 showed that this gene was expressed in
5 various human tissues including heart, brain, placenta, lung, and muscle. Four separate mRNA transcripts of about 4.0, 5.5, 7.0, and 9.0 kilobases in length were detected. Northern analysis of expression of gene 036 in
10 normal human colon and human colon tumor samples showed two messages of about 4.0 kb and about 7.0 kb in normal colon cells and in a few colon tumors.

The gene 036 cDNA described herein encodes a protein having 740 amino acids. The nucleic acid sequence of a cDNA clone of gene 036 is shown in Fig. 2
15 (SEQ ID NO: 6), along with the deduced amino acid sequence (SEQ ID NO: 7) of the protein encoded by gene 036. As noted above, genes that are expressed at a higher level in normal cells than tumor cells are candidate tumor suppressor genes. Accordingly gene 036
20 and the protein it encodes can be used to interfere with the growth of tumors, particularly colon tumors. Methods related to the use of tumor suppressor genes and proteins are described in U.S. Patent Nos. 5,532,220; 5,527,676; and 5,552,283.

25 The gene 036 nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or RNA, and can be double-stranded or single-stranded (*i.e.*, either a sense or an antisense strand). Fragments of these molecules are also considered within the scope of
30 the invention, and can be produced, for example, by the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule can be produced by *in vitro* transcription. Preferably, the nucleic acid

- 89 -

molecules encode polypeptides that, regardless of length, are soluble under normal physiological conditions.

The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that
5 differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide (for example, the polypeptide of SEQ ID NO: 7). In addition, these nucleic acid molecules are not limited to sequences that only encode polypeptides, and
10 thus, can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence.

The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such as
15 the cell of a mammal. Thus, the nucleic acids can be those of a human, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, dog, or cat. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.

20 In addition, the isolated nucleic acid molecules of the invention encompass fragments that are not found as such in the natural state. Thus, the invention encompasses recombinant molecules, such as those in which a nucleic acid molecule (for example, an isolated nucleic
25 acid molecule encoding gene 036 protein) is incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location). Recombinant nucleic acid
30 molecules and uses therefor are discussed further below.

In the event the nucleic acid molecules of the invention encode or act as antisense molecules, they can be used for example, to regulate translation of gene 036 mRNA. Techniques associated with detection or regulation
35 of gene 036 expression are well known to skilled artisans

- 90 -

and can be used to diagnose and/or treat inflammation or disorders associated with cellular proliferation.

The invention also encompasses nucleic acid molecules that hybridize under stringent conditions to a
5 nucleic acid molecule encoding a gene 036 polypeptide. The gene 036 cDNA sequence described herein (SEQ ID NO: 6) can be used to identify these nucleic acids, which include, for example, nucleic acids that encode homologous polypeptides in other species, and splice
10 variants of the gene in humans or other mammals. Accordingly, the invention features methods of detecting and isolating these nucleic acid molecules. Using these methods, a sample (for example, a nucleic acid library, such as a cDNA or genomic library) is contacted (or
15 "screened") with a gene 036-specific probe (for example, a fragment of SEQ ID NO:6 that is at least 12 nucleotides long). The probe will selectively hybridize to nucleic acids encoding related polypeptides (or to complementary sequences thereof). The probe, which can contain at
20 least 12 (for example, 15, 25, 50, 100, or 200 nucleotides) can be produced using any of several standard methods (see, for example, Ausubel et al., "Current Protocols in Molecular Biology, Vol. I," Green Publishing Associates, Inc., and John Wiley & Sons,
25 Inc., NY, 1989). For example, the probe can be generated using PCR amplification methods in which oligonucleotide primers are used to amplify a specific nucleic acid sequence that can be used as a probe to screen a nucleic acid library, as described in Example 1 below, and
30 thereby detect nucleic acid molecules (within the library) that hybridize to the probe.

One single-stranded nucleic acid is said to hybridize to another if a duplex forms between them. This occurs when one nucleic acid contains a sequence
35 that is the reverse and complement of the other (this

- 91 -

same arrangement gives rise to the natural interaction between the sense and antisense strands of DNA in the genome and underlies the configuration of the "double helix"). Complete complementarity between the
5 hybridizing regions is not required in order for a duplex to form; it is only necessary that the number of paired bases is sufficient to maintain the duplex under the hybridization conditions used.

Typically, hybridization conditions are of low to
10 moderate stringency. These conditions favor specific interactions between completely complementary sequences, but allow some non-specific interaction between less than perfectly matched sequences to occur as well. After hybridization, the nucleic acids can be "washed" under
15 moderate or high conditions of stringency to dissociate duplexes that are bound together by some non-specific interaction (the nucleic acids that form these duplexes are thus not completely complementary).

As is known in the art, the optimal conditions for
20 washing are determined empirically, often by gradually increasing the stringency. The parameters that can be changed to affect stringency include, primarily, temperature and salt concentration. In general, the lower the salt concentration and the higher the
25 temperature, the higher the stringency. Washing can be initiated at a low temperature (for example, room temperature) using a solution containing a salt concentration that is equivalent to or lower than that of the hybridization solution. Subsequent washing can be
30 carried out using progressively warmer solutions having the same salt concentration. As alternatives, the salt concentration can be lowered and the temperature maintained in the washing step, or the salt concentration can be lowered and the temperature increased. Additional
35 parameters can also be altered. For example, use of a

- 92 -

destabilizing agent, such as formamide, alters the stringency conditions.

In reactions where nucleic acids are hybridized, the conditions used to achieve a given level of stringency will vary. There is not one set of conditions, for example, that will allow duplexes to form between all nucleic acids that are 85% identical to one another; hybridization also depends on unique features of each nucleic acid. The length of the sequence, the composition of the sequence (for example, the content of purine-like nucleotides versus the content of pyrimidine-like nucleotides) and the type of nucleic acid (for example, DNA or RNA) affect hybridization. An additional consideration is whether one of the nucleic acids is immobilized (for example, on a filter).

An example of a progression from lower to higher stringency conditions is the following, where the salt content is given as the relative abundance of SSC (a salt solution containing sodium chloride and sodium citrate; 2X SSC is 10-fold more concentrated than 0.2X SSC). Nucleic acids are hybridized at 42°C in 2X SSC/0.1% SDS (sodium dodecylsulfate; a detergent) and then washed in 0.2X SSC/0.1% SDS at room temperature (for conditions of low stringency); 0.2X SSC/0.1% SDS at 42°C (for conditions of moderate stringency); and 0.1X SSC at 68°C (for conditions of high stringency). Washing can be carried out using only one of the conditions given, or each of the conditions can be used (for example, washing for 10-15 minutes each in the order listed above. Any or all of the washes can be repeated. As mentioned above, optimal conditions will vary and can be determined empirically.

A second set of conditions that are considered "stringent conditions" are those in which hybridization is carried out at 50°C in Church buffer (7% SDS,

- 93 -

0.5% NaHPO₄, 1 M EDTA, 1% BSA) and washing is carried out at 50°C in 2X SSC.

Once detected, the nucleic acid molecules can be isolated by any of a number of standard techniques (see, 5 for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual," 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

The invention also encompasses: (a) expression vectors that contain any gene 036 protein-related coding 10 sequences and/or their complements (that is, "antisense" sequence); (b) expression vectors that contain any of the foregoing gene 036 protein-related coding sequences operatively associated with a regulatory element (examples of which are given below) that directs the 15 expression of the coding sequences; (c) expression vectors containing, in addition to sequences encoding a gene 036 polypeptide, nucleic acid sequences that are unrelated to nucleic acid sequences encoding gene 036 polypeptide, such as molecules encoding a reporter or 20 marker; and (d) genetically engineered host cells that contain any of the foregoing expression vectors and thereby express the nucleic acid molecules of the invention in the host cell.

Recombinant nucleic acid molecule can contain a 25 sequence encoding a soluble gene 036 polypeptide, mature gene 036 polypeptide, or gene 036 polypeptide having a signal sequence. These polypeptides may be fused to additional polypeptides.

The regulatory elements referred to above include, 30 but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements, which are known to those skilled in the art, and which drive or otherwise regulate gene expression. Such regulatory elements include but are not limited to the 35 cytomegalovirus hCMV immediate early gene, the early or

- 94 -

late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for
5 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

Similarly, the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences,
10 for example, sequences that function as a marker or reporter. Examples of marker or reporter genes include β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r , $G418^r$), dihydrofolate reductase
15 (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware
20 of additional useful reagents, for example, of additional sequences that can serve the function of a marker or reporter. Generally, the hybrid polypeptide will include a first portion and a second portion; the first portion being a gene 036 polypeptide and the second portion
25 being, for example, the reporter described above or an immunoglobulin constant region.

The expression systems that may be used for purposes of the invention include, but are not limited to, microorganisms such as bacteria (for example, *E. coli*
30 and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, *Saccharomyces* and *Pichia*) transformed with recombinant yeast expression vectors
35 containing the nucleic acid molecules of the invention.

- 95 -

(e.g., SEQ ID NO:6); insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecules of the invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (for example, Ti plasmid) containing gene 036 nucleotide sequences; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions containing gene 036 polypeptides or for raising antibodies to those polypeptides, vectors that are capable of directing the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791, 1983), in which the coding sequence of the insert may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye and Inouye, Nucleic Acids Res. 13:3101-3109, 1985; Van Heeke and Schuster, J. Biol. Chem. 264:5503-5509, 1989); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins

- 96 -

are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa
5 protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhidrosis virus (AcNPV) can be used as a vector to express foreign genes. The virus grows in
10 *Spodoptera frugiperda* cells. The coding sequence of the insert may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion
15 of the coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera*
20 *frugiperda* cells in which the inserted gene is expressed. (for example, see Smith et al., *J. Virol.* 46:584, 1983; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an
25 adenovirus is used as an expression vector, the nucleic acid molecule of the invention may be ligated to an adenovirus transcription/translation control complex, for example, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the
30 adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (for example, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a gene 036 gene product in infected hosts (for
35 example, see Logan and Shenk, Proc. Natl. Acad. Sci. USA

- 97 -

81:3655-3659, 1984). Specific initiation signals may also be required for efficient translation of inserted nucleic acid molecules. These signals include the ATG initiation codon and adjacent sequences. In cases where
5 an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the coding sequence is
10 inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert.
15 These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see
20 Bittner et al., *Methods in Enzymol.* 153:516-544, 1987).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for
25 example, glycosylation) and processing (for example, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and
30 gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary
35 transcript, glycosylation, and phosphorylation of the

- 98 -

gene product may be used. The mammalian cell types listed above are among those that could serve as suitable host cells.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the gene 036 protein and polypeptide sequences described above may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (for example, promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express gene 036 protein. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the gene product.

A number of selection systems can be used. For example, the herpes simplex virus thymidine kinase (Wigler, et al., Cell 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, Proc. Natl. Acad. Sci. USA 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, et al., Cell 22:817, 1980) genes can be employed in tk⁻, hgp^rt⁻ or apr^t- cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler

- 99 -

et al., Proc. Natl. Acad. Sci. USA 77:3567, 1980; O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, Proc. Natl. Acad. Sci. USA 78:2072, 1981); neo, 5 which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., J. Mol. Biol. 150:1, 1981); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147, 1984).

Alternatively, any fusion protein may be readily 10 purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Proc. Natl. Acad. Sci. USA 88: 8972-8976, 1991). 15 In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia 20 virus are loaded onto Ni²⁺-nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

Gene 036 Polypeptides

The gene 036 polypeptides described herein are 25 those encoded by any of the nucleic acid molecules described above and include gene 036 protein fragments, mutants, truncated forms, and fusion proteins. These polypeptides can be prepared for a variety of uses, including but not limited to the generation of 30 antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products or compounds that can modulate expression or activity of gene 036 protein.

The invention also encompasses polypeptides that 35 are functionally equivalent to gene 036 protein. These

- 100 -

polypeptides are equivalent to gene 036 protein in that they are capable of carrying out one or more of the functions of gene 036 protein in a biological system. Preferred gene 036 polypeptides have 20%, 40%, 50%, 75%,
5 80%, or even 90% of the activity of the full-length, mature human form of gene 036 protein described herein. Such comparisons are generally based on an assay of biological activity in which equal concentrations of the polypeptides are used and compared. The comparison can
10 also be based on the amount of the polypeptide required to reach 50% of the maximal stimulation obtainable.

Functionally equivalent proteins can be those, for example, that contain additional or substituted amino acid residues. Substitutions may be made on the basis of
15 similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Amino acids that are typically considered to provide a conservative substitution for one another are specified in the summary
20 of the invention.

Polypeptides that are functionally equivalent to gene 036 protein (SEQ ID NO:7) can be made using random mutagenesis techniques well known to those skilled in the art (and the resulting mutant gene 036 proteins can be
25 tested for activity). It is more likely, however, that such polypeptides will be generated by site-directed mutagenesis (again using techniques well known to those skilled in the art). These polypeptides may have an increased function, i.e., a greater ability to inhibit
30 cellular proliferation, or to evoke an inflammatory response. Such polypeptides can be used to protect progenitor cells from the effects of chemotherapy and/or radiation therapy.

To design functionally equivalent polypeptides, it
35 is useful to distinguish between conserved positions and

- 101 -

variable positions. This can be done by aligning the sequence of gene 036 cDNAs that were obtained from various organisms. Skilled artisans will recognize that conserved amino acid residues are more likely to be
5 necessary for preservation of function. Thus, it is preferable that conserved residues are not altered.

Mutations within the gene 036 protein coding sequence can be made to generate gene 036 proteins that are better suited for expression in a selected host cell.
10 For example, N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety
15 of amino acid substitutions at one or both of the first or third amino acid positions of any one or more of the glycosylation recognition sequences which occur (in N-X-S or N-X--), and/or an amino acid deletion at the second position of any one or more of such recognition
20 sequences, will prevent glycosylation at the modified tripeptide sequence (see, for example, Miyajima et al., EMBO J. 5:1193, 1986).

The polypeptides of the invention can be expressed fused to another polypeptide, for example, a marker
25 polypeptide or fusion partner. For example, the polypeptide can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein or a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells. The gene 036
30 polypeptides of the invention, or a portion thereof, can also be altered so that it has a longer circulating half-life by fusion to an immunoglobulin Fc domain (Capon et al., Nature 337:525-531, 1989). Similarly, a dimeric form of the gene 036 protein polypeptide can be produced,
35 which has increased stability *in vivo*.

- 102 -

The polypeptides of the invention can be chemically synthesized (for example, see Creighton, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., NY, 1983), or, perhaps more
5 advantageously, produced by recombinant DNA technology as described herein. For additional guidance, skilled artisans may consult Ausubel et al. (*supra*), Sambrook et al. ("Molecular Cloning, A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), and,
10 particularly for examples of chemical synthesis Gait, M.J. Ed. ("Oligonucleotide Synthesis," IRL Press, Oxford, 1984).

The invention also features polypeptides that interact with gene 036 protein (and the genes that encode
15 them) and thereby alter the function of gene 036 protein. Interacting polypeptides can be identified using methods known to those skilled in the art. One suitable method is the "two-hybrid system," which detects protein interactions *in vivo* (Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578, 1991). A kit for practicing this
20 method is available from Clontech (Palo Alto, CA).

Gene 036 and the protein encoded by gene 036, can be used in any of the applications described herein. In addition, portions of the 036 gene, e.g., the portion
25 described on identified as SEQ ID NO: 2 or the portion identified as SEQ ID NO: 4, can be used in any of the applications described herein.

Gene 036 and the protein encoded by gene 036 can be used in screening assays to identify compounds that
30 alter the expression or activity of the protein encoded by gene 036. In such screening assays the level of expression or activity is measured in the presence and absence of a selected compound. These two measurements are then compared to determine whether the selected
35 compound alters expression or activity. Similar assays

- 103 -

can be used to compare the effect of a selected compound on expression or activity to the effect of a compound known to alter expression or activity.

Compounds which alter the expression of the gene
5 036 protein can be used therapeutically for treatment of disorders associated with aberrant expression of gene 036.

Other Embodiments

It is to be understood that while the invention
10 has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are
15 within the scope of the following claims.

What is claimed is:

- 104 -

1. A method of diagnosing a tumor in a mammal, said method comprising:

obtaining a test sample of tissue cells from the mammal;

5 obtaining a control sample of known normal cells from the same type of tissue; and

detecting in both the test sample and the control sample the level of expression of gene 097, wherein a level of expression higher in the test sample than in the
10 control sample indicates a tumor in the test sample.

2. A method of claim 1, wherein the tissue is colon tissue.

3. A method of diagnosing a tumor in a mammal, said method comprising:

15 obtaining a test sample of tissue cells from the mammal;

obtaining a control sample of known normal cells from the same type of tissue; and

detecting in both the test sample and the control
20 sample the level of expression of any one or more of genes 030, 036, or 056 wherein a level of expression lower in the test sample than in the control sample indicates a tumor in the test sample.

4. A method of claim 3, wherein the tissue is
25 colon tissue.

5. A method of treating a tumor in a mammal, said method comprising administering to the mammal a compound in an amount effective to decrease the level of expression or activity of the gene transcript or gene

- 105 -

product of gene 097, to a level effective to treat the tumor.

6. A method of claim 5, wherein the tumor is a colon tumor.

5 7. A method of claim 5, wherein said compound is an antisense or ribozyme molecule that blocks translation of the gene transcript.

8. A method of claim 5, wherein said compound is a nucleic acid complementary to the 5' region of gene
10 097, and blocks formation of a gene transcript via triple helix formation.

9. A method of claim 5, in which the compound is an antibody that neutralizes the activity of the gene product.

15 10. A method of treating a tumor in a mammal, said method comprising administering to the mammal a compound in an amount effective to increase the level of expression or activity of the gene transcript or gene product of any one or more of genes 030, 036, and 056, to
20 a level effective to treat the tumor.

11. A method of claim 10, wherein the tumor is a colon tumor.

12. A method of claim 7, wherein the compound comprises a nucleic acid whose administration results in
25 an increase in the level of expression of any one of genes 030, 036, and 056, thereby ameliorating symptoms of the tumor.

- 106 -

13. A method for inhibiting tumors in a mammal,
said method comprising administering to the mammal a
normal allele of one or more of genes 030, 036, and 056,
so that a gene product is expressed, thereby inhibiting
5 tumors.

14. A method for treating tumors in a mammal,
said method comprising administering to the mammal an
effective amount of a gene product of any one or more of
genes 030, 036, and 056.

10 15. A method of monitoring the efficacy of a
compound in clinical trials for inhibition of tumors in a
patient, said method comprising
obtaining a first sample of tumor tissue cells
from the patient;
15 administering the compound to the patient;
after a time sufficient for the compound to
inhibit the tumor, obtaining a second sample of tumor
tissue cells from the patient; and
detecting in the first and second samples the
20 level of expression of gene 097, wherein a level of
expression lower in the second sample than in the first
sample indicates that the compound is effective to
inhibit a tumor in the patient.

16. A method of claim 15, wherein the tissue is
25 colon tissue.

17. A method of monitoring the efficacy of a
compound in clinical trials for inhibition of tumors in a
patient, said method comprising
obtaining a first sample of tumor tissue cells
30 from the patient;
administering the compound to the patient;

- 107 -

after a time sufficient for the compound to inhibit the tumor, obtaining a second sample of tumor tissue cells from the patient; and

detecting in the first and second samples the
5 level of expression of any one or more of genes 030, 036, and 056, wherein a level of expression higher in the second sample than in the first sample indicates that the compound is effective to inhibit a tumor in the patient.

18. A method of claim 17, wherein the tissue is
10 colon tissue.

19. An isolated nucleic acid molecule encoding a gene 036 polypeptide.

20. The isolated nucleic acid molecule of claim 19, said molecule comprising a nucleotide sequence
15 encoding a polypeptide having sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:7.

21. The isolated nucleic acid molecule of claim 19, said molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:7.

20 22. The isolated nucleic acid molecule of claim 19, said molecule comprising the nucleotide sequence of between nucleotide 449 and 2665, inclusive, of SEQ ID NO:6.

23. The isolated nucleic acid molecule of claim
25 19, said molecule hybridizing to a nucleic acid molecule having the sequence of nucleotides 449 to 2665, inclusive, of SEQ ID NO:6 or its complement.

- 108 -

24. The isolated nucleic acid molecule of claim 23, said hybridization taking place under stringent conditions.

25. A host cell comprising the isolated nucleic acid molecule of claim 19.

26. A nucleic acid vector comprising the nucleic acid molecule of claim 19.

27. The nucleic acid vector of claim 26, wherein said vector is an expression vector.

28. The vector of claim 27, further comprising a regulatory element.

29. The vector of claim 28, wherein the regulatory element is selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early promoter of SV40 adenovirus, the late promoter of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

30. The vector of claim 28, wherein said regulatory element directs tissue-specific expression.

31. The vector of claim 26, further comprising a reporter gene.

- 109 -

32. The vector of claim 31, wherein the reporter gene is selected from the group consisting of β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside
5 phosphotransferase (neo^r, G418^r), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT).

33. The vector of claim 26, wherein said vector
10 is a plasmid.

34. The vector of claim 26, wherein said vector is a virus.

35. The vector of claim 34, wherein said virus is a retrovirus.

15 36. A substantially pure gene 036 polypeptide.

37. The polypeptide of claim 36, said polypeptide comprising an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:7.

38. The polypeptide of claim 37, said polypeptide
20 comprising an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:7.

39. An antibody that selectively binds to a gene 036 polypeptide.

40. The antibody of claim 39, wherein said
25 antibody is a monoclonal antibody.

- 110 -

41. A pharmaceutical composition comprising the polypeptide of claim 36.

42. A method of identifying a compound that modulates the expression of gene 036, said method
5 comprising comparing the level of expression of gene 036 in a cell in the presence and absence of a selected compound, wherein a difference in the level of expression in the presence and absence of said selected compound indicates that said selected compound modulates the
10 expression of gene 036.

43. A method of identifying a compound that modulates the activity of gene 036 protein, said method comprising comparing the level of activity of gene 036 protein in a cell in the presence and absence of a
15 selected compound, wherein a difference in the level of activity in the presence and absence of said selected compound indicates that said selected compound modulates the activity of gene 036 protein.

44. A method for treating a patient suffering
20 from a disorder associated with excessive expression or activity of gene 036 protein, comprising administering to said patient a compound which inhibits expression or activity of gene 036 protein.

45. A method for treating a patient suffering
25 from a disorder associated with insufficient expression or activity of gene 036 protein, comprising administering to said patient a compound which increases expression or activity of gene 036 protein.

- 111 -

46. A method for diagnosing a disorder associated with aberrant expression of gene 036 protein, comprising obtaining a biological sample from a patient and measuring gene 036 expression in said biological sample, wherein increased or decreased gene 036 protein expression in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of gene 036 protein.

47. A method for diagnosing a disorder associated with aberrant activity of gene 036 protein, comprising obtaining a biological sample from a patient and measuring gene 036 activity in said biological sample, wherein increased or decreased gene 036 activity in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant activity of gene 036 protein.

Fig. 1a (SEQ ID NO: 1)

rohc030

AGGTGACCGTGACCTGAGAAGGAAAGAAAGATCCTCTGCTGACCCCTGGAGC
AGCTCTCGAGAACTACCTGTTGGTATTGTCCACAAGCTCTCCCGAGCGCCCAT
CTTGTGCCATGTTTTAAGTCTTCATGGATGTTCTGCATGTCATGGGGACTAAA
ACTACCCAACAGATCTTCCAGAGGTCCATGGTGGAAGACGATAACCCTGTG
AAATACTTTATAAAATGTCTTAATGTCCAAAAAAAAAAAA

Fig. 1b (SEQ ID NO: 2)

rohc036

TTTTTTTTTTTTTGGCGAGGTGGGAATGCCCCACAGGCACTGGGGATGCACTGAC
TGGTGAGGAGGCCTCTGCAAAGAAGGAAGGAGGAGGTATAGGCTGGTACC
GAGTACACTGACGAAGCCTGCACATTCGTAGGTGAGGCAGCATTCACTGGCCG
GGGAGGAAGAGCTTGCTTCATGGCCAGGGCTGAATTGACCTTGACTGATGACT
TCTGGGGGAGGCCATCCTTTCATCTGGAGGTGGAAAGTAAACAAGGATGC
ATTGAGCTGATACGGTTGGTGCTTCATGACATCTAATGCATTGAGGGGTTTCT
TTCCCTTTTTTTTGGCCATTTTGGAGGGCTGTGCAGCTGATGGCTGAGAYYTKG
MRAGCAGCCAGTGGGTAAGACGGCGATTGAAG

Fig. 1c (SEQ ID NO: 3)

rohc056

GGCTAACCGAGAGAGCCGTATATTAATTAATCCTGGAAACCATCTTAAGATC
CAAGAAGGTACTTTAGGATTTTTTCATCGCAAGTGATGCCAAAGAAGTTAAAA
GGGCATTTTTTTTACTGCAAGGCCTGTCATGATGACATCACAGATCCCAAAAGA
ATAAAAAAATGTGGCTGCAAACGGCTCAAGGTTGCAGCTAGATCACGCTATT
CCAAAGATCCATTTGAGTTCAAGAAGGAGACTCCCAATTCTCGGCTTGTGACC
GAGCCAGTTGAAGATGAGCAGCCGTCAACACTATCACCAAAAAAAAAAAAA

Fig. 1d (SEQ ID NO: 4)

rohc095

CTTACACAGAGGGGACAAGGTGGAGATGTTACCAGACACCACAGGCAAGGG
AGCCCTCATGTTTGTCAAGAGGAGGGAGAGAATGGATCAGATCACAGCCCAA
AAAAAAAAAAAA

Fig. 1e (SEQ ID NO: 5)

rohc097

GGCTTGACGACAAGCAGAAGCCAGTTATGATGACAGGTGATAGATCCAAA
ATAATTGCCACATTTGTTAACATTTTTCCATTTCTAAACCATCCTTAAAGAAA
ATCATATATGGGGTCACACCATCCTCACGGTAGTCCAATAGAGCAACCATGCC
ATCTGGATTGATGTTTTACCAATAAAGAACTGGTAGTTTTTGAAATTAGCA
AGGATGTGCTTGATTGTTCTGCAGCCCTGTCATAAAAGGTTTTACTCTTCT
GGTCTCTGTTCTTCAAGTTTCCCTTTGATTGATTTCATGTAATCTTTGATGTACT
TCTTGTCGTCCAAGC

FIG. 2 (SHEET 1 of 3)

GGAGAGACTANCGGCCCTAGTGGCCCTTTAGTGGCTCTCCCGGAGCTGAAAAATCTAAGTCTCCTGACCCAGACCCCTA	75 (SEQ ID NO: 6)
ACTTGTCACATGACAGGATTOTCCACATAAATTCGATCCCTACTAATGAGAAAGCAGACCCCTTCTGAGGTCCAGCAA	158
GATAATCCAGATCTCCAGTGGCAGAGAGTTGAGAGTGATCCAGGAAAGTGAAGCAGGAGATGGGGGACTGCCCGGGGTG	237
GAAGTGATCTCTGACTGCTCTGACAGGCAGAAGACAGAAGGGTGACAGCTTCAGGCAGGAAAGGAGTGTGTGGATTCTC	316
CAGTGGAAAGGAGGGCAGTCAGAAGCACCTCTCTCTGGTATCCTTTGCCGTCTCATCAGAAGGCACAGAGCAGGGAGA	395
AGATCCACGCTCGAAAAAGATCACAGCAGACCTCACAAGCACCGAGCGCGGC	
M H G S G G ATG CAC GGC TCA GGA GGA	6 (SEQ ID NO: 7)
S E S L S E K Q V K E A K S K C K S I A	26
AGT GAA AGC CTG TCA GAA AAA CAA GTG AAG GAA GCA AAA TCT AAA TGC AAA AGC ATT GCC	526
L L L T D A P N P N S K G V L M F K K R	46
CTT CTT CTA ACG GAT GCT CCC AAC CCC AAC TCC AAG GGG GTG TTG ATG TTT AAG AAG CGA	586
R R R A R K Y T L V S Y G T G E L E R E	66
CGT CGG AGG GCC AGG AAA TAC ACC CTA GTT AGC TAC GGT ACT GGC GAG CTT GAG CGA GAG	646
A D E E E E G D K E D T C E V A F L G A	86
GGC GAC GAG GAG GAA GAA GGT GAC AAG GAG GAT ACA TGT GAA GTA GCA TTT CTT GGT GCA	706
S E S E V D E E L L S D V D D N T Q V V	106
AGC GAA TCA GAG GTG GAT GAA GAG TTA TTG TCT GAC GTT GAC GAC AAC ACA CAA GTT GTG	766
N F D W D S G L V D I E K K L N R G D K	126
AAC TTT GAC TGG GAT TCT GGA CTG GTG GAC ATT GAA AAG AAA CTG AAC AGA GGG GAC AAG	826
M E M L P D T T G K G A L M F V K R R E	146
ATG GAG ATG TTA CCA GAC ACC ACA GGC AAG GGA GCC CTC ATG TTT GTC AAG AGG AGG GAG	886
R M D Q I T A Q K E E D K V G G T P S R	166
AGA ATG GAT CAG ATC ACA GCC CAA AAA GAA GAG GAC AAG GTA GGT CGA ACG CCA AGC AGA	946
E Q D A A Q T D G L R T T T S Y Q R K E	186
GAA CAA GAT GCT GCC CAG ACC GAT GGC CTG AGA ACC ACG ACT TCT TAC CAA AGA AAG GAG	1006
E E S V R T Q S S V S K S Y I E V S H G	206
GAA GAG TCG GTA AGA ACG CAG ACC TCT GTG AGC AAA AGC TAC ATC GAG GTG AGT CAT GGT	1066
L G H V P Q Q N G F S G A S E T A N I Q	226
CTT GGC CAT GTT CCC CAA CAG AAT GGC TTC AGT GGG GCA TCT GAG ACA GCA AAC ATC CAG	1126
R M V P M N R T A K P P P G S V N Q P A	246
AGG ATG GTC CCC ATG AAT AGA ACG GCC AAA CCC TTC CCA GGG TCT GTG AAT CAG CCA GCT	1186
T P F S P T R N M T S P I A D F P A P P	266
ACC CCC TTC TCG CCA ACC CGA AAC ATG ACG AGT CCC ATT GCT GAC TTT CCT GCA CCT CCA	1246
P Y S A V T P P P D A F S R G V S S P I	286
CCT TAC TCT GCA GTC ACT CCT CCC CCT GAC GCC TTC TCC AGA GGG GTT TCA AGT CCG ATT	1306
A G P A Q P P P W P Q P A P W S Q P A P	306
GCT GGC CCA GCA CAG CCC CCT CCA TGG CCC CAG CCT GCC CCG TGG TCC CAG CCA GCC TTT	1366

FIG. 2 (SHEET 2 OF 3)

Y D S S B R I A S R D E R I S V P A K R 326
 TAC GAT TOG TCT GAG CGA ATA GCT TCC CGA GAT GAG AGG ATC TCA GTG CCA GCA AAA AGA 1426

 T G I L Q E K K R R S T T K P M P T P R 346
 ACA GGA ATA TTG CAG GAG GCC AAA AGG AGA AGC ACG ACA AAA OCC ATG TTT ACT TTT AAA 1486

 E P K V S P N P E L L S L L Q N S E G R 366
 GAG CCC AAA GTA AGC CCA AAT CCT GAA CTC TTG TCA CTC CTT CAA AAT TCA GAA GGC AAA 1546

 R G T G A G G D S G P E E D Y L S L G A 386
 CCG GGC ACT GGA GCT GGA GGT GAT TCC GGA CCG GAA GAA GAC TAC CTC AGC TTG GGG GCA 1606

 E A C N P M Q S S S A K Q K T P P P V A 406
 GAG GCT TGT AAT TTC ATG CAA AGC TCC TCT GCC AAA CAA AAG ACC CCT OCT OCT GTT GCT 1666

 P K P A V K S S S S Q P V T P V S P V W 426
 CCA AAA CCT GCA GTC AAG TCC TCA TCC TCC CAA CCA GTA ACT CCA GTT TCC CCA GTC TGG 1726

 S P G V A P T Q P P A F P T S N P S K G 446
 TCT CCA GGA GTG GCT CCC ACC CAA CCT OCT GCC TTC CCC ACA TCC AAC CCA TCA AAG GGC 1786

 T V V S S I K I A Q P S Y P P A R P A S 466
 ACC GTT GTC TCC TCC ATC AAA ATA GCC CAG OCT TCT TAC OCT OCT GGC GGG OCT GCA AGT 1846

 T L N V A G P F K G P Q A A V A S Q N Y 486
 ACT TTG AAC GTG GCT GGT CCC TTC AAA GGA CCA CAA GCA GCA GTA GCC AGT CAG AAT TAC 1906

 T P K P T V S T P T V N A V Q P G A V G 506
 ACA CCC AAA CCA ACA GTT TCC ACA CCA ACA GTC AAT GCT GTT CAG OCT GGT GCA GTG GGA 1966

 P S N E L P G M S G R G A Q L F A K R Q 526
 CCA TCC AAT GAG CTT CCA GGA ATG AGT GGG AGA GGA GCT CAG CTC TTT GCT AAA AGG CAG 2026

 S R M E K Y V V D S D T V Q A H A A R A 546
 TOG AGA ATG GAG AAG TAT GTG GTC GAT TCA GAC ACG GTG CAG GCC CAC GCT GCT CCA GCT 2086

 Q S P T P S L P A S W K Y S S N V R A P 566
 CAG TCT CCC ACT CCA TCT CTC CCG GCC AGT TOG AAG TAC TCC TCC AAT GTC CCA GCA OCT 2146

 P P V A Y N P I H S P S Y P L A A L K S 586
 OCT OCT GTG GGC TAT AAT OCT ATC CAC TOG CCG TCT TAC CCA CTG GCT GCT CTC AAG TCT 2206

 Q P S A A Q P S K M G K K K G R K P L N 606
 CAG CCA TCA GCT GCA CAG CCC TCC AAA ATG GGC AAG AAA AAG GGA AAG AAA CCC CTC AAT 2266

 A L D V M K H Q P Y Q L N A S L F T F Q 626
 GCA TTA GAT GTC ATG AAG CAG CAA CCG TAT CAG CTC AAT GCA TCC TTG TTT ACT TTC CAA 2326

 P P D A K D G L P Q K S S V K V N S A L 646
 OCT CCA GAT GCA AAG GAT GGC CTC CCC CAG AAG TCA TCA GTC AAG GTC AAT TCA GGC CTG 2386

 A M K Q A L P P R P V N A A S P T N V Q 666
 GCC ATG AAG CAA GCT CTT OCT CCC CCG CCA GTG AAT GCT GCC TCA OCT ACG AAT GTG CAG 2446

 A S S V Y S V P A Y T S P P S P F A E A 686
 GCT TOG TCA GTG TAC TOG GTA CCA GCC TAT ACC TCT OCT OCT TCC TTC TTT GCA GAG GCC 2506

 S S P V S A S P V P V G I P T S P K Q E 706

FIG. 2 (SHEET 3 of 3)

TCC TCA CCA GTC AGT GCA TCC CCA GTG CCT GTG GGC ATT CCC ACC TCG CCA AAG CAA GAA	2566
S A S S S Y F V A P R P K F S A K K S G	725
TCA GCC TCA TCA TCT TAT TTT GTG GCA CCA AGG CCA AAG TTC TCA GCC AAG AAA AGT GGT	2626
V T I Q V W K P S V V E E *	740
GTG ACA ATT CAG GTG TGG AAA CCA TCT GTT GTG GAA GAG TAA	2668
TCTTGTA ^Δ GCTGAAGCTGAGTGTCCACTTTGCTTGAAATGAATTGTTTGCASTGTTCTTGAGTCCCTGAGAATGCCTAG	2747
CAAAGTCTCAACTTACTTAATTTCAGATATGTCACCTCCTAATCTGGGTCCAAGGAGTATAATATTTTTTAATGAGTCA	2826
AAAATCCAACCTCAGATTGACCTAAAATATATTTATCTTCTTTGCACACTTAAAAAATCCAGGAGCACCCCAAAATAGAC	2905
ATGTACCGTTATATTAAAGTAAGCAGGAGACTTAGGATTGTGCTGTAGCCACAAGAAAGACAGTGATCAGTGATATCAA	2984
ACATCAGGAATCAGCCTTTATGTAAACATAACAGCTGTCTCTATGGTGAAAGGTTCAAATGTAGTGAAGGTATAACST	3063
ATATTGACTGAGATTTCCCTTTTAGGTAGTGCCTTATCTCTATTACTAGTGTAAAGGAGGGGGGGCC	3131

١٢٢٢ ١٢٢٢ ١٢٢٢ ١٢٢٢ ١٢٢٢ ١٢٢٢ ١٢٢٢ ١٢٢٢ ١٢٢٢ ١٢٢٢

Fig. 1a (Seq ID No. 1)

roh030

AGGTGACCGTGACCTGAGAAGGAAAGAAAGATCCTCTGCTGACCCCTGGAGC
AGCTCTCGAGAACTACCTGTTGGTAATTGTCCACAAGCTCTCCCGAGCGCCCAT
CTTGCGCCATGTTTAAAGTCTTCATGGATGTTCTGCAATGTCATGGGGACTAAA
ACTCACCCAAACAGATCTTCCAGAGGTCCATGGTGAAGACGATAACCCCTGTG
AAATACTTTATAAAATGTCTTAATGTCCAAAAAAAAAAAA

Fig. 1b (Seq ID No. 2)

roh036

TTTTTTTTTTTTGGCGAGGTGGGAATGCCCCACAGGCACTGGGGATGCACTGAC
TGGTGAGGAGGCCTCTGCAAAGAAGGAAGGAGGAGGTATAGGCTGGTACC
GAGTACACTGACGAAGCCTGCACATTCGTAGGTGAGGCAGCAATCACTGGCCG
GGGAGGAAGAGCCTTGCTTCATGGCCAGGGCTGAATTGACCTGACTGATGACT
TCTGGGGGAGGCCATCCTTGCATCTGCAGGTGGAAAGTAAACAAGGATGC
ATTGAGCTGATACGGTGGTGGTTCATGACATCTAATGCATTGAGGGGTTTCT
TTCCCTTTTTTTGGCCATTTTGGAGGGCTGTGCAGCTGATGGCTGAGAYYTKG
MRAGCAGCCAGTGGGTAACACGGCGATTGAAG

Fig. 1c (Seq ID No. 3)

roh056

GGCTAACCGAGAGAGCCGTATATTAATTAATCCTGGAAACCATCTTAAGATC
CAAGAAGGTACTTTAGGATTTTTCATCGCAAGTGATGCCAAAGAAGTTAAAA
GGGCATTTTTTTACTGCAAGGCCCTGTCATGATGACATCACAGATCCCAAAGA
ATAAAAAAATGTGGCTGCAAACGGCTCAAGGTGCAGCTAGATCACGCTATT
CCAAAGATCCATTTGAGTTCAAGAAGGAGACTCCCAATCTCGGCTTGTGACC
GAGCCAGTTGAAGATGAGCAGCCGTCAACACTATCACCAAAAAAAAAAAAA

Fig. 1d (Seq ID No. 4)

roh095

CTTACACAGAGGGGACAAGGTGGAGATGTTACCAGACACCACAGGCAAGGG
AGCCCTCATGTTTGTCAAGAGGAGGGAGAGAATGGATCAGATCACAGCCCAA
AAAAAAAAAAAA

Fig. 1e (Seq ID No. 5)

roh097

GGCTTGGAAGACAAGCAGAAGCCAGTTATGATGACAGGTGATAGATCCAAA
ATAATTGCCACATTTGTTAACATTTTCCATTTCTAAACCATCCTTAAAGAAA
ATCATATATGGGGTCACACCATCTCACGGTAGTCCAATAGAGCAACCATGCC
ATCTGGATTCAATGTTTCACCAATAAAGAACTGGTAGTTTGAATTAGCA
AGGATGTGCTTGATTTGTTCTGCAAGCCCTGTCAATAAAGGTTTACTCTTCT
GGTCTCTGTTCTTCAAGTTTCCCTTTGATTTGATTTCAATCTTTGATGTA
TCTTGTGCTCCAAGC

FIG. 2 (SHEET 1 of 3)

GCACAGACTATACCCCTGAGTGGCCCTTCTAGTGGCTGTGCGGAGCTGAAAAATCTAAGTCTCTGACCCAGACCTTA	75(SEQ ID NO: 6)
ACTTCTCAGCTGACGATTTCTCCATAAATTCATCCCTACTATATGAGGAGAGACCTTTCTGAGCTGACGAA	150
GATAATCCAGTCTCTGAGTGGCAGAGTTGAGAGTATCTGAGGAATGAGGACGAGTCTCTGAGCTGACGAA	237
GAAATGAGTCTCTGAGTGGCAGAGTTGAGAGTATCTGAGGAATGAGGACGAGTCTCTGAGCTGACGAA	316
CAGTGGAGAGGAGGAGTCTGAGAGGAGTCTCTGAGTGGCTGAGTGGCTGAGTGGCTGAGTGGCTGAGTGGCT	395
AGATCCAGCTCTGAAAAAGATCCAGAGAGCTTCAAGGAGCTGAGGAGGAG	466
5(SEQ ID NO: 7)	
M K G S G D ATG CAC GGC TCA GGA GGA	466
S E S L S E K Q V K E A R S K C K S I A	18
AGT GAA AGC CTG TCA GAA AAA CAA GTG AAG GAA GCA AAA TCT AAA TGC AAA AGC ATT GTC	526
L L L T D A P N P N S K G V L H F E K R	48
CTT GTT CTA AGC GAT GCT GGC AAC GGC AAC TGC AAG GGG GTG TTG ATG TTT AAG AAG CCA	586
R R R A R E Y T L V S V Q T E E L E R E	68
GCT GGG AGT GGC AGG AAA TAC ACC CTA GTT AGC TAC GGT ACT GGC GAG CTT GAG CCA GAG	646
A D E E E E G D K E D T C E V A F L G A	86
GCG GAC GAG GAG GAA GAA GGT GAC AAG GAG GAT ACA TGT GAA GTA CCA TTT CTT GGT GCA	706
S E S E V D E E L L S D V D D E T Q V V	106
AGC GAA TCA GAG GTG GAT GAA GAG TTA TTG TCT GAC GTT GAC GAC AAC ACA CAA GTT GTG	746
N P D W D S G L V D I E R K L N R G D R	126
AAC TTT GAC TGG GAT TCT GGA CTG GTG GAC ATT GAA AAG AAA CTG AAC AGA GGC GAC AAG	826
K E H L P D T T G K G A L H P V K R R E	146
ATG GAG ATG TTA CCA GAC AGC ACA GGC AAG GGA GGC CTC ATG TTT GTC AAG AGG AGC GAG	886
A M D Q I T A Q K E E D K V G G T P S R	166
ATA ATG GAT CAG ATC ACA GTC CAA AAA GAA GAG GAC AAG GTA GTT GGA AGG CCA AGC AGA	946
E Q D A A Q T D G L R T T T S Y Q R K E	186
GAA CAA GAT GGT GGC CAG AGC GAT GGC CTG AGA AGC AGG ACT TCT TAC CAA AGA AAG GAG	1006
E E S V R T D E S V S K S Y I E V S H G	206
GAA GAG TCG GGA AGA AGG CAG AGC TCT GTG AGC AAA AGC TAC ATC GAG GTG AGT CAG GAT	1066
L G H V P Q Q W G F S G A B E T A N I Q	226
CTT GGC CAT GTT GGC CAA CAG AAT GGC TTC AGT GGC CCA TCT GAG AGA CCA AAC ATC CAG	1126
R M V P M M R T A K P P P O S V N Q P A	246
AGG ATG GTC GGC AGT AAT AGA AGG GGC AAA GGC TTC CCA GGC TCT GTG AAT CAG CCA GCT	1186
T P F S P T R N E T S P I A D F P A P P	266
AGC GGC TTC TCG CCA ACC CCA AAC ATG AGG AGT GGC AAT GCT GAC TTT GCT GCA CTT CCA	1246
P Y S A V T P P P D A F B R G V S S P I	286
GCT TAC TCT GCA GTC ACT GAT GGC GCT GAC GGC TTC TCG AGA GGC GTT TCA AGT GGC AAT	1306
A G P A Q P P P W P Q P A P W S Q P A P	306
GCT GGC CCA CCA CAG GCT GCT CCA TGG GTC CAG GCT GGC GGC TCG TCG CAG CCA GGC TTT	1366

FIG. 2 (SHEET 2 of 3)

Y	B	S	S	B	R	I	A	S	R	D	S	R	I	S	V	P	A	X	R	126
TAC	GAT	TGG	TCT	GAG	CDA	ATA	GCT	TCC	CGA	CAT	GAG	AGG	ATC	TCA	GTG	CCA	GCA	AAA	AGA	1426
T	G	I	L	Q	Z	R	K	R	S	T	T	K	P	M	F	T	P	R		346
ACA	GGA	ATA	TTG	CAG	UAG	GCC	AAA	AGG	AGA	AGC	AGG	ACA	AAA	CCC	ATG	TTT	ACT	TTT	AAA	1686
E	P	K	V	B	P	N	P	E	L	L	S	L	L	Q	M	S	E	O	X	366
GAG	CCC	AAA	GTA	AGC	CCA	AAT	CCT	AAA	CTC	TTG	TCA	CTC	CTT	CRA	AMT	TCA	GAA	GTC	AAA	1546
R	O	T	G	A	G	O	D	S	O	P	E	E	D	Y	L	S	L	G	A	386
CGG	GCC	ACT	BGA	GCT	GGA	GAT	GAT	TCC	GGA	CCG	GAA	GAA	GAC	TAC	CTC	AGC	TTG	GCG	GCA	1806
E	A	C	N	F	M	Q	S	S	S	A	X	Q	K	T	P	P	P	V	A	406
CGG	GCT	TGT	AAT	TTC	ATG	CRA	AGC	TCC	TCT	GCC	AAA	CRA	AGG	ACC	CTT	CCC	CCT	GCT	GCT	1686
P	K	F	A	V	K	S	S	S	S	Q	P	V	T	P	V	E	V	V	N	426
CCA	AAA	CCG	CCA	GTG	ANG	TCC	TCA	TCC	TCC	CAA	CCA	GTG	ACT	CCA	GTT	TCC	CCA	GTG	TGG	1726
S	P	O	V	A	F	T	Q	P	P	A	F	P	T	S	N	P	S	R	G	446
TCT	CCA	GGA	GTG	GCT	CCC	AGC	CRA	CCT	CCT	GCC	TTC	CCC	ACA	TCC	AGC	CCA	TCA	AGG	GCC	1786
T	V	V	S	S	I	K	I	A	Q	P	S	Y	P	P	A	R	P	A	S	466
AGC	GTC	GTG	TCC	TCC	ASC	AAA	MEA	GCC	CAG	CCT	TCT	TAC	CCT	CCT	CCC	CGG	CCT	GCA	AGT	1846
T	L	N	V	A	G	P	F	K	Q	P	Q	A	A	V	A	S	Q	R	Y	486
ACT	TTG	AGC	GTG	GCT	GCT	CCC	TTC	AAA	CCA	CCA	CAA	CCA	CCA	GTA	GCC	AGT	CHG	AAT	TAC	1906
T	P	E	P	T	V	S	T	P	T	V	N	A	V	G	P	G	A	V	G	506
ACA	CCC	AAA	CCA	ACA	GTT	TCC	ACA	CCA	ACA	GTG	AAT	GCT	GTT	CAG	CCT	GCT	GCA	GTG	GGA	1966
F	S	N	R	L	P	G	N	E	G	R	G	A	Q	L	F	A	K	R	G	526
CCA	TCC	AAT	GAG	CTT	CCA	GGA	ATG	AGT	GCC	AGA	GGA	GCT	CAG	CTC	TTT	GCT	AAA	AGG	CAI	2026
S	R	N	E	K	Y	V	V	D	S	D	T	V	Q	A	K	A	A	R	A	546
TCC	AAA	ATG	GAG	ANG	TAT	GTC	GTC	GAT	TCA	DAC	AGG	GTG	CAG	GTC	CAC	GCT	GCT	CCA	GCT	2086
Q	S	P	T	P	S	L	F	A	E	N	K	Y	S	S	N	V	R	A	P	566
CAG	TCT	CCC	ACT	CCA	TCT	CTC	CCC	CCC	AGT	TGG	ANG	TAC	TCC	TCC	AAT	GTG	GGA	GCA	CCT	2146
P	P	V	A	Y	N	P	I	K	S	P	S	Y	P	L	A	A	L	K	S	586
CCT	CCT	GTG	GCC	TAT	AAT	CCT	AGC	CAC	TCC	CCC	TCT	TAC	CCA	CTG	GCT	GCT	CTC	AGG	TCT	2206
Q	P	B	A	A	Q	P	S	K	K	O	K	K	K	G	K	K	P	L	N	606
CAG	CCA	TCA	GCT	GCA	CAG	GTC	TCC	AAA	ATG	GCC	AGG	AAA	ANG	GGA	ANG	AAA	CCC	CTC	AAT	2266
A	L	D	V	M	K	H	Q	P	Y	Q	L	N	A	S	L	P	T	P	Q	626
GCA	TTA	GAT	GTG	ATG	ANG	CAC	GGA	CCC	TAT	CAG	CTC	AAT	GCA	TCC	TTG	TTT	ACT	TTC	GAA	2326
P	P	D	A	E	D	G	L	P	Q	K	S	S	V	K	V	S	S	A	L	646
CCT	CCA	GAT	GCA	ANG	GAT	GCC	CTC	CCC	CAG	AAG	TCA	TCA	GTG	AGG	GTG	AAT	TCA	CCC	CTG	2386
A	N	R	Q	R	L	P	P	R	P	V	N	A	A	S	P	T	N	V	Q	666
GCC	ATG	AGG	CAA	GCT	CCT	CCT	CCC	CGG	CCA	GTG	AAT	CCT	CCC	TCA	CCT	AGG	AAT	GTG	CAG	2446
A	S	S	V	Y	S	V	P	A	Y	T	S	S	P	B	F	F	A	E	A	686
GCT	TGG	TCA	GTC	TAC	TGG	GTA	CCA	CCC	TAT	ACT	TCT	CCT	CCT	TCC	TTT	GCA	CAG	CTC		2506
S	S	P	V	S	A	S	P	V	P	V	D	I	P	T	S	P	K	Q	E	706

FIG. 2 (SHEET 3 of 3)

TGC TCA CCA GTC AGT GCA TGC CCA GTG OCT GTG GGC ATT CCC AGC TGC CCA AAG CAA GAA 2566
 S A S S S Y P V A P R P K F S A K R S G 725
 TCA GGC TCA TCA TCT TAT TTT GTG GCA CCA AGG CCA AAG TTC TCA GGC AAG AAA AGT GGT 2626
 V T I Q V N K P S V V E E * 740
 GTC ACA ATT CAG GTG TGC AAA CCA TCT GTT GTG GAA GAG TAA 2658
 TCTTGACCTGAAAGCTGAGTGTCCACTTTCCTTGAATTAATTTGTTTGCAGTGTTCCTTCAGTCCCTGAGAAATGCCTAG 2747
 CAAAGTCCCTCAACTTACTTAATTTCAATATATGTCACCTCTCTATCTGGGTTCTAGGAGTATATATTTTAAATGAGTCA 2826
 AAAATCCACTCAGATTCACTTAAATATTTATCTTTCTTTCACCTTAAATATCCAGGACACCCCAATATATC 2905
 ATGTACCCCTATATTAAGTAAAGGAGTACTTTCGATTGTCTCTAGCCACAAAGACATGATCAGTCACTATCAA 2984
 AACTCAGGATCAGCCCTTTCTGTACATTAAGCTCTCTCTCTATCTGAAAGCTTCAAAATGTAGTGAAGTATCACT 3063
 ATATTCAGTGAATTTCCCTTTTACGATTAATGCTTATCTTATTTACTAGTGTAAAGGATTTCTTCTC 3131

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A3	(11) International Publication Number: WO 97/33551 (43) International Publication Date: 18 September 1997 (18.09.97)
(21) International Application Number: PCT/US97/04191 (22) International Filing Date: 14 March 1997 (14.03.97) (30) Priority Data: 60/013,438 15 March 1996 (15.03.96) US (71) Applicant: MILLENNIUM PHARMACEUTICALS [US/US]; 640 Memorial Drive, Cambridge, MA 02110 (US). (72) Inventor: SHYJAN, Andrew, W.; 25 Baker Road, Nahant, MA 01908 (US). (74) Agents: FASSE, J., Peter et al.; Fish and Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i> (88) Date of publication of the International search report: 16 October 1997 (16.10.97)
(54) Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF NEOPLASTIC CELL GROWTH AND PROLIFERATION (57) Abstract The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that are differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04191

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68

US CL : 435/6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SEAYER. Monoclonal Antibodies in Industry: More Difficult Than Originally Thought. Genetics Engineering News. August 1994, Vol. 14, No. 14, pages 10 and 14.	1-2

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

&

document member of the same patent family

Date of the actual completion of the international search

07 AUGUST 1997

Date of mailing of the international search report

29 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JULIE E. REEVES

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04191

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1,2

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04191

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-2, drawn to method of diagnosing a tumor by detecting the 097 gene product.

Group II, claim(s) claims 3-4, drawn to the method of diagnosing a tumor by detecting the expression of the 030, 036 or 056 gene.

Group III, claim(s) 5-8 (in part) and 12, drawn to a method of treating a tumor by administering a compound effective in decreasing the level of expression of the gene transcript of gene 097. Group III is limited to treatments by administration of nucleic acids to limit gene expression.

Group IV, claim(s) 5-6 (in part) and 9, drawn to a method of treating a tumor by administering a compound effective in decreasing the level of activity of the gene product of gene 097. Group IV is limited to treatments by administration of antibodies to limit gene product activity.

Group V, claim(s) 10-11 and 45 (in part), drawn to a method of treating a tumor by administering a compound effective in increasing the level of expression of the gene transcript of gene 030, 036 or 056. Claim 45 has been included in this Group to the extent that it reads upon the administration of a compound that increases the expression of gene 036.

Group VI, claim(s) 13, drawn to a method of treating a tumor by administering a normal allele of gene 030, 036 or 056.

Group VII, claim(s) 14, drawn to a method of treating a tumor by administering protein product of gene 030, 036 or 056.

Group VIII, claim(s) 15-16, drawn to a method for monitoring the efficacy of a compound for clinical trials for inhibition of tumors by detecting low levels of expression of gene 097.

Group IX, claim(s) 17-18, drawn to a method for monitoring the efficacy of a compound for clinical trials for inhibiting a tumor by detecting an increase in the expression of gene 030, 036 or 056.

Group X, claim(s) 19-25 drawn to the nucleic acid encoding the 036 polypeptide.

Group XI, claim(s) 26-35, drawn to vectors containing DNA encoding for the 036 gene, including reporter genes, promoters and plasmids, viruses and retroviruses.

Group XII, claim(s) 36-38 and 41, drawn to the 036 gene product polypeptide and the pharmaceutical compound containing the polypeptide of gene 036.

Group XIII, claim(s) 39-40, drawn to an antibody specific for the gene 036 polypeptide.

Group XIV, claim(s) 42, drawn to a method for identifying compounds that modulate the expression of gene 036.

Group XV, claim(s) 43, drawn to a method of identifying compounds that modulates the activity of gene 036 polypeptide.

Group XVI, claim(s) 44 (in part), drawn to a method of treating a patient by administering a compound that inhibits the expression of gene 036.

Group XVII, claim(s) 44 (in part), drawn to a method of treating a patient by administering a compound that inhibits the activity of gene 036 polypeptide.

Group XVIII, claim(s) 45 (in part), drawn to a method of treating a patient by administering a compound that increases the activity of gene 036 polypeptide.

Group XIX, Claim 46, drawn to a method of diagnosing a disorder associated with aberrant expression of gene 036

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/04191

protein.

Group XX, Claim 47, drawn to a method of diagnosing a disorder associated with aberrant activity of gene 036 protein.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. If an election is made of any of Groups II, V, VI, VII, or IX, the species are as follows:

Species A: gene 030
Species B: gene 036
Species C: gene 056.

The inventions listed as Groups I-XVII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups II and I are both method of diagnosing that lack an inventive concept as Group II relies on the special technical feature of detecting gene 06 gene expression and Group I relies on the special technical feature of detecting gene 097 gene expression.

Groups III-IX and Groups XIII-XX are all methods of treatment that lack a single inventive concept as they have special technical features not found in the other Groups. For example Group III recites the special technical feature of the administration of gene 097 nucleic acid that is not found in the other groups. Group IV recites the special technical feature of the administration of an antibody specific for gene 097 product that is not found in the other groups. Group V recites the special technical feature of the administering a compound effective in increasing expression of gene 036 that is not found in the other groups. Group VI recites the special technical feature of the administration of the normal 036 allele is not found in the other groups. Group VII recites the special technical feature of administering the 036 protein product that is not found in the other Groups. Group VIII recites the special technical feature of detecting low levels of the gene 097 expression. Group IX recites the special technical feature of detecting an increase in the expression of the 030, 036 or 056 genes. Group XIV recites the special technical feature of administering compounds that modulate the expression of the gene 036. Group XV recites the special technical feature of administering compounds that modulate the activity of the gene 036. Group XVI recites the special technical feature of treating a patient by administering a compound that inhibits the expression of the 036 polypeptide. Group XVII recites the special technical feature of treating a patient by administering a compound that inhibits the activity of the 036 protein. Group XVIII recites the special technical feature of administering a compound that increases the activity of the 036 protein. Group XIX recites the special technical feature of diagnosing a disorder associated with aberrant 036 gene expression while Group XX recites the special technical feature of diagnosing a disorder associated with aberrant 036 gene activity.

Groups X-XIII are all products that lack a single inventive concept. Group X recites the special technical feature of an isolated nucleic acid encoding the 036 polypeptide. Group XI recites the special technical feature of vectors containing the 036 gene. Group XII recites the special technical feature of a pharmaceutical compound containing the gene 036 polypeptide product that is not found in the other Groups. Group XIII recites the special technical feature of an antibody specific for the 036 protein that is not found in the other groups.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The proteins encoded by the gene 030, 036 and 056 have different amino acid sequences which would result in different tertiary structure and different biological functions, and thus represent distinct products.

Since Group II is the first group with species, all additional species must be paid for.